var title_f15_51_16176="Flock workers lung CT - Ground glass opacities";
var content_f15_51_16176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flock worker's lung CT - Ground glass opacities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 303px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prone CT of the chest shows ground glass opacification and patchy consolidation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Kern, MD and Robert Crausman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16176=[""].join("\n");
var outline_f15_51_16176=null;
var title_f15_51_16177="Posterior superior iliac spine";
var content_f15_51_16177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Posterior superior iliac spine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Illustration&nbsp;of the posterior pelvis. In most persons, the posterior superior iliac spine&nbsp;can be easily palpated as a bony prominence&nbsp;at the posterior end of the iliac crest. The bone marrow needle should be inserted at the top of this prominence (at the site of the asterisk). As shown by the arrow, it should be angled in the direction of the anterior superior iliac spine, a prominence found at the anterior end of the iliac crest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16177=[""].join("\n");
var outline_f15_51_16177=null;
var title_f15_51_16178="Cicatricial pemphigoid - gingiva";
var content_f15_51_16178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cicatricial pemphigoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erosions are present on the gingiva in this patient with cictricial pemphigoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16178=[""].join("\n");
var outline_f15_51_16178=null;
var title_f15_51_16179="Headache causes and diagnosis in adults";
var content_f15_51_16179=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/51/16179/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16179/contributors\" id=\"au1611\">",
"       Zahid H Bajwa, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16179/contributors\" id=\"au4358\">",
"       R Joshua Wootton, MDiv, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/51/16179/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16179/contributors\" id=\"se7359\">",
"       Jerry W Swanson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/51/16179/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16179/contributors\" id=\"de6967\">",
"       John F Dashe, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/51/16179?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HEADACHE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Headaches can be quite debilitating, although most headaches are",
"     <strong>",
"      not",
"     </strong>",
"     caused by life-threatening disorders. Most headaches are caused by one of four syndromes (",
"     <a class=\"graphic graphic_table graphicRef76857 \" href=\"UTD.htm?41/59/42939\">",
"      table 1",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Tension-type headache",
"      </li>",
"      <li>",
"       Migraine headache",
"      </li>",
"      <li>",
"       Chronic daily headache",
"      </li>",
"      <li>",
"       Cluster headache",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The causes and diagnosis of non-migraine headaches are discussed here. Migraine headaches are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=see_link\">",
"      \"Patient information: Migraine headaches in adults (Beyond the Basics)\"",
"     </a>",
"     .) A summary of headache treatments is also available. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"      \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .) A discussion of headaches in children is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=see_link\">",
"      \"Patient information: Headache in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TENSION TYPE HEADACHE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of tension type headaches (TTH) include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pressure or tightness around both sides of the head or neck",
"      </li>",
"      <li>",
"       Mild to moderate pain that is steady and does not throb",
"      </li>",
"      <li>",
"       Pain is not worsened by activity",
"      </li>",
"      <li>",
"       Pain can increase or decrease in severity over the course of the headache",
"      </li>",
"      <li>",
"       There may be tenderness in the muscles of the head, neck, or shoulders",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     People with TTH often feel stress or tension before their headache. Unlike migraine, tension headaches occur without other symptoms such as nausea, vomiting, sensitivity to lights and sounds, or an aura. However, some people have symptoms of both tension and migraine headache.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      MIGRAINE HEADACHES",
"     </span>",
"    </p>",
"    <p>",
"     Migraine headaches are a type of headache that causes moderate to severe pain that is worsened by light, noise, and motion. Some people also experience nausea and vomiting. Migraine headaches typically last for a few hours, but may last for as long as three days. Migraines are discussed in detail in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=see_link\">",
"      \"Patient information: Migraine headaches in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CLUSTER HEADACHE",
"     </span>",
"    </p>",
"    <p>",
"     Cluster headaches are severe, debilitating headaches that occur repeatedly for weeks to months at a time, followed by periods with no headache. Cluster headaches are relatively uncommon, affecting less than one percent of people. Men are affected more commonly than women, with a peak age of onset of 25 to 50 years.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cluster headaches:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Begin quickly without any warning and reach a peak within a few minutes.",
"      </li>",
"      <li>",
"       The headache is usually deep, excruciating, continuous, and explosive in quality, although occasionally it may be pulsatile and throbbing.",
"      </li>",
"      <li>",
"       The attack may occur up to eight times per day but is usually short in duration (between 15 minutes and three hours).",
"      </li>",
"      <li>",
"       The pain typically begins in or around the eye or temple; less commonly it starts in the face, neck, ear, or side of the head.",
"      </li>",
"      <li>",
"       The pain is always on one side.",
"      </li>",
"      <li>",
"       Most people with cluster headache are restless and may pace or rock back and forth when an attack is in progress.",
"      </li>",
"      <li>",
"       Cluster headaches are associated with eye redness and tear production on the side of the pain, a stuffy and runny nose, sweating, and pale skin.",
"      </li>",
"      <li>",
"       Some people are light sensitive in the eye on the affected side.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Cluster headaches can begin at any age. People with cluster headaches are more likely to have family members who also have cluster headaches. Drinking alcohol can bring on a cluster headache.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CHRONIC DAILY HEADACHE",
"     </span>",
"    </p>",
"    <p>",
"     Some people develop very frequent headaches, as frequent as every day in some cases. When a headache is present for more than 15 days per month for at least three months, it is described as a chronic daily headache.",
"    </p>",
"    <p>",
"     Chronic daily headache is not a type of headache but a category that includes frequent headaches of various kinds. Most people with chronic daily headache have migraine or tension-type headache as the underlying type of headache. They often start out having an occasional migraine or tension-type headache, but the headaches became more frequent over months or years. Some people with frequent headache use headache medications too often, which can lead to \"medication-overuse headaches\" (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Medication-overuse headache'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Medication-overuse headache",
"     </span>",
"     &nbsp;&mdash;&nbsp;Medication-overuse headache (MOH) may occur in people who have frequent migraine, cluster, or tension-type headaches, which leads them to overuse pain medications. A vicious cycle occurs whereby frequent headaches cause the person to take medication frequently (often non-prescription medication), which then causes a rebound headache as the medication wears off, causing more medication use, and so on.",
"    </p>",
"    <p>",
"     Overuse of any number of pain medications can increase the risk of developing medication-overuse headaches. To avoid medication-overuse headaches, we recommend the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       If possible, avoid butalbital combinations (Fiorinal&reg;, Fioricet&reg;, Esgic&reg;) and narcotics completely.",
"      </li>",
"      <li>",
"       Do not use triptans (Imitrex&reg; and others) or",
"       <span class=\"nowrap\">",
"        aspirin/acetaminophen/caffeine",
"       </span>",
"       combinations (Excedrin&reg;) more than nine days per month.",
"      </li>",
"      <li>",
"       Do not use NSAIDS (eg, ibuprofen, Advil, Motrin, aspirin) more than 15 days per month.",
"      </li>",
"      <li>",
"       Do not take acetaminophen (eg, Tylenol&reg;) more than two times per week.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you have frequent headaches, you may need a preventive medication. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"      \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      OTHER TYPES OF HEADACHE",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of other causes of headache.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Sinus headache",
"     </span>",
"     &nbsp;&mdash;&nbsp;Recurrent headaches related to sinus infections are uncommon. Many, if not most, people diagnosed with sinus headaches actually have migraine headaches. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=see_link\">",
"      \"Patient information: Migraine headaches in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Sinus-related pain usually lasts for several days (unlike a typical migraine) and does not cause nausea, vomiting, or sensitivity to noise or light (as seen in migraine) [",
"     <a class=\"abstract\" href=\"UTD.htm?15/51/16179/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"      \"Patient information: Chronic rhinosinusitis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Post-trauma headaches",
"     </span>",
"     &nbsp;&mdash;&nbsp;Headaches that occur within one to two days after a head injury are relatively common. Most people report a generalized dull, aching, constant discomfort that worsens intermittently. Other common symptoms include vertigo (sensation of spinning), lightheadedness, difficulty concentrating, problems with memory, becoming tired quickly, and irritability.",
"    </p>",
"    <p>",
"     Post-trauma headaches may continue for up to a few months, although anyone with a headache that does not begin to improve within a week or two after a traumatic event should be evaluated. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"      \"Concussion and mild traumatic brain injury\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      HEADACHE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Clinicians typically use a person's description of their headache, in combination with an examination, to determine the type of headache. Some people have more than one type of headache.",
"    </p>",
"    <p>",
"     Most people do not need x-rays or imaging tests. A CT scan (or MRI) may be recommended in some circumstances, for example, if symptoms are unusual, if there are any danger signs (see",
"     <a class=\"local\" href=\"#H13\">",
"      'Headache danger signs'",
"     </a>",
"     below), or if there are any abnormalities seen during the examination. Other possible reasons for brain imaging include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Headaches that steadily worsen despite treatment",
"      </li>",
"      <li>",
"       A sudden change in the pattern of headaches",
"      </li>",
"      <li>",
"       Signs or symptoms that suggest that another medical condition may be causing symptoms",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      HEADACHE DANGER SIGNS",
"     </span>",
"    </p>",
"    <p>",
"     The vast majority of headaches are not life threatening. You should seek medical attention immediately if your headache:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Comes on suddenly, becomes severe within a few",
"       <strong>",
"        seconds",
"       </strong>",
"       or",
"       <strong>",
"        minutes",
"       </strong>",
"       , or that could be described as \"the worst headache of your life\"",
"      </li>",
"      <li>",
"       Is severe and occurs with a fever or stiff neck",
"      </li>",
"      <li>",
"       Occurs with a seizure, personality changes, confusion, or passing out",
"      </li>",
"      <li>",
"       Begins quickly after strenuous exercise or minor injury",
"      </li>",
"      <li>",
"       Is new and occurs with weakness, numbness, or difficulty seeing. While migraine headaches can sometimes cause these symptoms, you should be evaluated urgently the first time these symptoms appear.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If you have persistent or frequent headaches, headaches that interfere with normal activities, or your headaches become more painful, you should see a healthcare provider during normal office hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Headaches and brain tumor",
"     </span>",
"     &nbsp;&mdash;&nbsp;Headaches occur in approximately 50 percent of people who have brain tumors. However, headaches are very common and brain tumors are",
"     <strong>",
"      rarely",
"     </strong>",
"     found in people who are evaluated for headaches. Many people with brain tumors have chronic headaches that are worse with bending over or occur with nausea and vomiting, although these symptoms can also occur with headaches not related to a brain tumor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      HEADACHE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of headaches is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"      \"Patient information: Headache treatment in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804367002\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15026600\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/31/3570?source=see_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/29/27090?source=see_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/47/8947?source=see_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/42/26274?source=see_link\">",
"      Patient information: Arteriovenous malformations in the brain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/34/6690?source=see_link\">",
"      Patient information: Astrocytoma (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15026615\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/57/35731?source=see_link\">",
"      Patient information: Migraine headaches in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/59/42931?source=see_link\">",
"      Patient information: Headache treatment in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36086?source=see_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/58/42915?source=see_link\">",
"      Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21194?source=see_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"      Basilar-type migraine",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/61/7128?source=see_link\">",
"      Chronic migraine",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3898?source=see_link\">",
"      Cluster headache: Acute and preventive treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14327?source=see_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/38/35433?source=see_link\">",
"      Estrogen-associated migraine",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34615?source=see_link\">",
"      Evaluation of headache in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39704?source=see_link\">",
"      Evaluation of the adult with headache in the emergency department",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5114?source=see_link\">",
"      Headache in pregnancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3624?source=see_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32953?source=see_link\">",
"      Headache, migraine, and stroke",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5700?source=see_link\">",
"      Hypnic headache",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35879?source=see_link\">",
"      Medication overuse headache: Etiology, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37830?source=see_link\">",
"      Overview of chronic daily headache",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/56/42889?source=see_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37079?source=see_link\">",
"      Tension-type headache in adults: Acute treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32441?source=see_link\">",
"      Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1433?source=see_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12601?source=see_link\">",
"      Thunderclap headache",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29626?source=see_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/headache.html\">",
"      www.nlm.nih.gov/medlineplus/headache.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Neurological Disorders and Stroke",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ninds.nih.gov/disorders/headache/headache.htm\">",
"      www.ninds.nih.gov/disorders/headache/headache.htm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Headache Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.achenet.org/resources/information_for_patients/\">",
"      www.achenet.org/resources/information_for_patients/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/51/16179/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/51/16179?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16179/abstract/1\">",
"      Cady RK, Dodick DW, Levine HL, et al. Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment. Mayo Clin Proc 2005; 80:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16179/abstract/2\">",
"      Levine HL, Setzen M, Cady RK, et al. An otolaryngology, neurology, allergy, and primary care consensus on diagnosis and treatment of sinus headache. Otolaryngol Head Neck Surg 2006; 134:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16179/abstract/3\">",
"      Dodick DW. Clinical practice. Chronic daily headache. N Engl J Med 2006; 354:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16179/abstract/4\">",
"      MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004; 63:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16179/abstract/5\">",
"      Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_51_16179=[""].join("\n");
var outline_f15_51_16179=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HEADACHE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TENSION TYPE HEADACHE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           MIGRAINE HEADACHES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CLUSTER HEADACHE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CHRONIC DAILY HEADACHE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           OTHER TYPES OF HEADACHE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           HEADACHE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           HEADACHE DANGER SIGNS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           HEADACHE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?41/59/42939\" title=\"table 1\">",
"           Headache syndromes PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16180="Beclomethasone (nasal): Patient drug information";
var content_f15_51_16180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Beclomethasone (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21109?source=see_link\">",
"     see \"Beclomethasone (nasal): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/34/7716?source=see_link\">",
"     see \"Beclomethasone (nasal): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7990246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Beconase AQ&reg;;",
"     </li>",
"     <li>",
"      Qnasl&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7990247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Beclomethasone&reg;;",
"     </li>",
"     <li>",
"      Mylan-Beclo AQ;",
"     </li>",
"     <li>",
"      Nu-Beclomethasone;",
"     </li>",
"     <li>",
"      Rivanase AQ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep nose polyps from coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness. It may take 2 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701592",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to beclomethasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your spray use with your doctor at each visit. Read and follow the facts on how to use the spray. Make sure you use the spray the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11052 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16180=[""].join("\n");
var outline_f15_51_16180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990247\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030250\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030252\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030251\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030256\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030257\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030259\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030254\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030255\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030260\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030261\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21109?source=related_link\">",
"      Beclomethasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/34/7716?source=related_link\">",
"      Beclomethasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30199?source=related_link\">",
"      Beclomethasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/17/26901?source=related_link\">",
"      Beclomethasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/13/44245?source=related_link\">",
"      Beclomethasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16181="Pityriasis rubra pilaris nails";
var content_f15_51_16181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Nail abnormalities in pityriasis rubra pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail thickening and subungual hyperkeratosis in patient with pityriasis rubra pilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16181=[""].join("\n");
var outline_f15_51_16181=null;
var title_f15_51_16182="Ventilator-associated lung injury";
var content_f15_51_16182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ventilator-associated lung injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16182/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16182/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16182/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16182/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16182/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16182/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/51/16182/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute lung injury that develops during mechanical ventilation is termed ventilator-induced lung injury (VILI) if it can be proven that the mechanical ventilation caused the acute lung injury. In contrast, ventilator-associated lung injury (VALI) exists if a causative relationship cannot be proven. VALI is the appropriate term in most clinical situations because it is virtually impossible to prove causation outside of the research laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, risk factors, incidence, prevention, clinical presentation, diagnosis, and management of VALI are discussed in this topic review. Other complications of mechanical ventilation are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alveolar overdistension and cyclic atelectasis are the principal causes of alveolar injury during positive pressure ventilation. Severe alveolar injury results in high permeability interstitial and alveolar edema, alveolar hemorrhage, hyaline membranes, loss of functional surfactant, and alveolar collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The relative importance of alveolar overdistension and cyclic atelectasis on the pathogenesis of VALI is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alveolar overdistension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung injury due to alveolar distension is referred to as alveolar strain. It reflects the presence of an elevated transpulmonary pressure (the difference between the airway pressure and the pleural pressure) or, more broadly, the ratio between the volume of gas delivered during a tidal breath and the amount of aerated lung receiving it [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/3\">",
"     3",
"    </a>",
"    ]. The following animal studies distinguish between the effect of volume and pressure on the lung. Specifically, they demonstrate that high tidal volumes cause lung injury, but high airway pressure does not:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rats were mechanically ventilated using high pressure plus high tidal volumes, low pressure plus high tidal volumes, or high pressure plus low tidal volumes [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/4\">",
"       4",
"      </a>",
"      ]. The only group that did not develop lung injury was the group ventilated with low tidal volumes (",
"      <a class=\"graphic graphic_figure graphicRef69085 \" href=\"UTD.htm?30/30/31214\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Two groups of rabbits were mechanically ventilated using a peak airway pressure of 15, 30, or 45 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O for one hour [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/5\">",
"       5",
"      </a>",
"      ]. One group of rabbits wore a body cast to limit thoracic expansion and eliminate the impact of volume, while the other group did not. The group without the body cast developed lung injury following mechanical ventilation at peak airway pressures of 30 and 45 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O. The group with the body cast did not develop lung injury at either peak airway pressure (",
"      <a class=\"graphic graphic_figure graphicRef69228 \" href=\"UTD.htm?32/2/32813\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also evidence that alveolar overdistension can induce or exacerbate lung injury in humans. In an observational study of 332 mechanically ventilated patients, high tidal volumes were identified as an independent risk factor for VALI (odds ratio 1.3, 95% CI, 1.12-1.51, for each mL above 6 mL per kg of ideal body weight) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large tidal volumes are not required for alveolar strain. When there is heterogeneous consolidation or atelectasis, a disproportionate volume from each breath is delivered to the open alveoli. This can cause focal alveolar overdistension and VALI despite delivery of conventional tidal volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/7\">",
"     7",
"    </a>",
"    ]. This can be conceptualized as delivering conventional tidal volumes to a \"baby lung\" (",
"    <a class=\"graphic graphic_figure graphicRef69702 \" href=\"UTD.htm?21/38/22126\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/8\">",
"     8",
"    </a>",
"    ]. Some clinicians believe that the opened portion of the lung is less likely to become injured than areas that are opened and closed with each breath, a phenomenon known as cyclic atelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cyclic atelectasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclic alveolar expansion (during inspiration) and collapse (during expiration) creates shear forces that distend adjacent alveoli and cause injury in animal models (",
"    <a class=\"graphic graphic_figure graphicRef52485 \" href=\"UTD.htm?19/24/19853\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This process is referred to as cyclical atelectasis, tidal atelectasis, or atelectrauma. It may explain why patients with a heterogeneous distribution of consolidation or atelectasis seem predisposed to VALI. Specifically, there are more alveoli that are exposed to the injurious impact of neighboring alveoli that are opening and collapsing when there is heterogeneous parenchymal disease. The contribution of cyclic atelectasis to ventilator induced lung injury compared to the contribution of alveolar strain is unknown; however, the mortality benefit of open lung ventilation suggests that it is significant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28519?source=see_link\">",
"     \"Inflammatory mechanisms of lung injury during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VALI is most common in patients receiving mechanical ventilation for the acute respiratory distress syndrome (ARDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2012 Berlin definition of ARDS includes the prior designation of acute lung injury (ALI) as mild ARDS. When research studies refer to patients with",
"    <span class=\"nowrap\">",
"     ALI/ARDS,",
"    </span>",
"    we use that rubric. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several explanations why patients with ARDS may be predisposed to VALI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An injured lung may be at risk for further injury",
"     </li>",
"     <li>",
"      Cyclic atelectasis is particularly common in an injured lung",
"     </li>",
"     <li>",
"      The heterogeneous distribution of disease facilitates focal alveolar overdistension despite conventional tidal volumes and exposes more healthy alveoli to the injurious effects of cyclic atelectasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VALI can occur in patients who are receiving mechanical ventilation for reasons other than ARDS. Risk factors for VALI include high tidal volumes (&gt;6 mL per kg of ideal body weight), blood product transfusions, acidemia (pH &lt;7.35), and restrictive lung disease, according to an observational study of 332 mechanically ventilated patients who did not have",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/6\">",
"     6",
"    </a>",
"    ]. Genetic variations have also been shown to place patients at increased risk for ALI and VALI, although none are currently used as markers or therapeutic targets [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/13-17\">",
"     13-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;VALI will develop in as many as 24 percent of patients who are receiving mechanical ventilation for reasons other than",
"    <span class=\"nowrap\">",
"     ALI/ARDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence is probably higher among patients who already have ARDS, but estimates vary widely [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/1\">",
"     1",
"    </a>",
"    ]. The variable estimates reflect the difficulty in distinguishing VALI from progressive ARDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have evaluated the effect of interventions that mitigate alveolar overdistension and cyclic atelectasis on important clinical outcomes in patients who are receiving mechanical ventilation for ARDS, including those with mild ARDS, formerly referred to as acute lung injury (ALI). These trials are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar clinical trials have not been conducted to look at the effect of the same interventions on the incidence or severity of VALI in patients who are receiving mechanical ventilation for reasons other than ARDS. Despite the lack of clinical data, it seems prudent to choose a ventilatory strategy that minimizes alveolar overdistension and cyclic atelectasis in all mechanically ventilated patients. Such strategies are relatively safe and might reduce VALI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventing alveolar overdistension &ndash; Alveolar overdistension is mitigated by using small tidal volumes, maintaining a low plateau pressure, and using pressure limited ventilation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Small tidal volumes mean that a smaller volume of gas is available to cause alveolar distension compared to traditional tidal volumes. In patients with",
"      <span class=\"nowrap\">",
"       ALI/ARDS,",
"      </span>",
"      randomized trials found that mechanical ventilation using tidal volumes of &le;6 mL per kg of ideal body weight (IBW) improved mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/18\">",
"       18",
"      </a>",
"      ]. This is referred to as low tidal volume ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The optimal tidal volume for patients who are mechanically ventilated for reasons other than ARDS is unknown. In a meta-analysis that included 15 randomized trials and 5 observational studies, the risks of lung injury and mortality were lower in patients ventilated with a tidal volume around 6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      rather than a larger volume (RR 0.33, 95%CI 0.23 to 0.47) and (RR 0.64, 95% CI 0.46 to 0.89), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/19\">",
"       19",
"      </a>",
"      ]. However, the analysis is limited by the large portion of patients from observational studies and the methodologic shortcomings of some trials. Thus, these findings will require large randomized trials before extending the use of low tidal volume ventilation to all ventilated patients. In the meantime, a tidal volume of approximately 6 to 8 mL per kg of IBW seems reasonable, albeit unproven (",
"      <a class=\"graphic graphic_table graphicRef87507 \" href=\"UTD.htm?8/22/8544\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef87147 \" href=\"UTD.htm?8/24/8576\">",
"       table 2",
"      </a>",
"      ). Low tidal volumes may create hypercapnia and require a strategy of permissive hypercapnic ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, low tidal volume ventilation may be difficult to achieve in some ICU patients without increased sedation, which carries other risks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=see_link\">",
"       \"Permissive hypercapnia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link\">",
"       \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low plateau airway pressures are associated with less alveolar distension. In an observational study of 30 patients being mechanically ventilated for",
"      <span class=\"nowrap\">",
"       ALI/ARDS,",
"      </span>",
"      a plateau airway pressure &lt;28 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O was associated with decreased focal alveolar hyperinflation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/21\">",
"       21",
"      </a>",
"      ]. This suggests that the optimal plateau airway pressure target may be lower than the traditional target of &lt;30 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O.",
"     </li>",
"     <li>",
"      Pressure limited ventilation (eg, pressure control) mitigates alveolar overdistension by ensuring that the target airway pressure is not surpassed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preventing cyclic atelectasis &ndash; Applied positive end-expiratory pressure (PEEP) is the principal method used to keep the alveoli open and lessen cyclic atelectasis. An optimal level of applied PEEP has not been established; however, the beneficial effects of PEEP at higher levels (ie, in the range of 15 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O) appear to outweigh the potentially detrimental effects due to alveolar strain, particularly in patients with a lot of recruitable lung [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Clinicians often aim for an applied PEEP that is greater than the lower inflection point on the pressure-volume curve because this amount of applied PEEP keeps the alveoli open and lessens cyclic atelectasis (",
"      <a class=\"graphic graphic_figure graphicRef72036 \" href=\"UTD.htm?31/39/32381\">",
"       figure 5",
"      </a>",
"      ). However, this strategy alone has not been shown to improve clinical outcomes and the appropriate level of applied PEEP is difficult to identify because accurate determination of the pressure-volume curve usually requires neuromuscular blockade. A novel approach to plot the pressure-volume curve without neuromuscular blockade has been used in several clinical trials and is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H22#H22\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'PV curves'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Open lung ventilation &ndash; Open lung ventilation is a ventilatory strategy that combines small tidal volumes (to lessen alveolar overdistension) and an applied PEEP above the low inflection point on the pressure-volume curve (to lessen cyclic atelectasis). The impact of open lung ventilation in patients who are mechanically ventilated for reasons other than ARDS has not been studied. In patients with",
"      <span class=\"nowrap\">",
"       ALI/ARDS,",
"      </span>",
"      randomized trials demonstrated that open lung ventilation improved clinical outcomes. However, more rigorous clinical trials are necessary to confirm these benefits. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H7#H7\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Open lung ventilation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of VALI is indistinguishable from progressive ARDS. Patients typically develop increased hypoxemia or require a greater fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) to maintain the same arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) or arterial oxyhemoglobin saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ). They may become more tachypneic and tachycardic. The chest radiograph typically shows new or increased bilateral interstitial or alveolar opacities of any severity. Computed tomography (CT) of the chest demonstrates heterogeneous consolidation and atelectasis, as well as focal hyperlucent areas that represent overdistended lung [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/1\">",
"     1",
"    </a>",
"    ]. VALI may be associated with multiple organ dysfunction syndrome (MODS) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VALI does not need to be distinguished from progressive ARDS because management is the same. In addition, definitive diagnosis of VALI may not be possible because of lack of pathognomonic features. Alternative causes of respiratory deterioration in mechanically ventilated patients (eg, lower respiratory infection, pulmonary edema) should always be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of VALI is the same as the management of ARDS due to other causes. Primary interventions include low tidal volume ventilation (tidal volume of 6",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    predicted body weight [PBW] and a plateau pressure of &le;30 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) (",
"    <a class=\"graphic graphic_table graphicRef87507 \" href=\"UTD.htm?8/22/8544\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87147 \" href=\"UTD.htm?8/24/8576\">",
"     table 2",
"    </a>",
"    ), a conservative fluid strategy, and supportive care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16182/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. The management of ARDS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventilator-associated lung injury (VALI) refers to an acute lung injury that develops during mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VALI is most common in patients receiving mechanical ventilation for acute respiratory distress syndrome (ARDS). However, VALI can occur in patients who are receiving mechanical ventilation for reasons other than ARDS. Other risk factors include large tidal volumes, blood product transfusions, acidemia, and restrictive lung disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that ALL mechanically ventilated patients be ventilated using a strategy that minimizes alveolar overdistension and cyclic atelectasis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The best data support using small tidal volumes (eg, 6 to 8",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      ideal body weight) and maintaining a low plateau airway pressure (",
"      <a class=\"graphic graphic_table graphicRef87507 \" href=\"UTD.htm?8/22/8544\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef87147 \" href=\"UTD.htm?8/24/8576\">",
"       table 2",
"      </a>",
"      ). Applied positive end expiratory pressure (PEEP), pressure limited ventilation and open lung ventilation are probably also beneficial. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VALI and progressive ARDS are clinically indistinguishable, but management is identical. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/1\">",
"      International consensus conferences in intensive care medicine: Ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societ&eacute; de R&eacute;animation de Langue Fran&ccedil;aise, and was approved by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999; 160:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/2\">",
"      Rouby JJ, Brochard L. Tidal recruitment and overinflation in acute respiratory distress syndrome: yin and yang. Am J Respir Crit Care Med 2007; 175:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/3\">",
"      Caironi P, Cressoni M, Chiumello D, et al. Lung opening and closing during ventilation of acute respiratory distress syndrome. Am J Respir Crit Care Med 2010; 181:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/4\">",
"      Dreyfuss D, Soler P, Saumon G. Mechanical ventilation-induced pulmonary edema. Interaction with previous lung alterations. Am J Respir Crit Care Med 1995; 151:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/5\">",
"      Hernandez LA, Peevy KJ, Moise AA, Parker JC. Chest wall restriction limits high airway pressure-induced lung injury in young rabbits. J Appl Physiol 1989; 66:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/6\">",
"      Gajic O, Dara SI, Mendez JL, et al. Ventilator-associated lung injury in patients without acute lung injury at the onset of mechanical ventilation. Crit Care Med 2004; 32:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/7\">",
"      Gattinoni L, Pesenti A. The concept of \"baby lung\". Intensive Care Med 2005; 31:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/8\">",
"      Gattinoni L, Pesenti A, Avalli L, et al. Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study. Am Rev Respir Dis 1987; 136:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/9\">",
"      Gattinoni L, Protti A, Caironi P, Carlesso E. Ventilator-induced lung injury: the anatomical and physiological framework. Crit Care Med 2010; 38:S539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/10\">",
"      Sugiura M, McCulloch PR, Wren S, et al. Ventilator pattern influences neutrophil influx and activation in atelectasis-prone rabbit lung. J Appl Physiol 1994; 77:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/11\">",
"      Muscedere JG, Mullen JB, Gan K, Slutsky AS. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med 1994; 149:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/12\">",
"      Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 2010; 303:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/13\">",
"      Arcaroli JJ, Hokanson JE, Abraham E, et al. Extracellular superoxide dismutase haplotypes are associated with acute lung injury and mortality. Am J Respir Crit Care Med 2009; 179:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/14\">",
"      Gao L, Grant A, Halder I, et al. Novel polymorphisms in the myosin light chain kinase gene confer risk for acute lung injury. Am J Respir Cell Mol Biol 2006; 34:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/15\">",
"      Arcaroli J, Sankoff J, Liu N, et al. Association between urokinase haplotypes and outcome from infection-associated acute lung injury. Intensive Care Med 2008; 34:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/16\">",
"      Hong SB, Huang Y, Moreno-Vinasco L, et al. Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med 2008; 178:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/17\">",
"      McClintock D, Zhuo H, Wickersham N, et al. Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury. Crit Care 2008; 12:R41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/18\">",
"      Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/19\">",
"      Neto AS, Cardoso SO, Manetta JA, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis. JAMA 2012; 308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/20\">",
"      Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med 1990; 16:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/21\">",
"      Terragni PP, Rosboch G, Tealdi A, et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. Am J Respir Crit Care Med 2007; 175:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/22\">",
"      Marcy TW, Marini JJ. Inverse ratio ventilation in ARDS. Rationale and implementation. Chest 1991; 100:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/23\">",
"      Pl&ouml;tz FB, Slutsky AS, van Vught AJ, Heijnen CJ. Ventilator-induced lung injury and multiple system organ failure: a critical review of facts and hypotheses. Intensive Care Med 2004; 30:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16182/abstract/24\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1598 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16182=[""].join("\n");
var outline_f15_51_16182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alveolar overdistension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cyclic atelectasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1598\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1598|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/30/31214\" title=\"figure 1\">",
"      Lung injury positive pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/2/32813\" title=\"figure 2\">",
"      Body cast prevents lung injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/38/22126\" title=\"figure 3\">",
"      Baby lung in ARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/24/19853\" title=\"figure 4\">",
"      Damaging shear forces in ARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/39/32381\" title=\"figure 5\">",
"      Tidal volume airway pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1598|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/22/8544\" title=\"table 1\">",
"      Predicted body weight and tidal volume for men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/24/8576\" title=\"table 2\">",
"      Predicted body weight and tidal volume for women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28519?source=related_link\">",
"      Inflammatory mechanisms of lung injury during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16183="Kawasaki disease: Complications";
var content_f15_51_16183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Kawasaki disease: Complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16183/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/51/16183/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2507732\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/1\">",
"     1",
"    </a>",
"    ]. KD also occurs rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 11 days without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/2\">",
"     2",
"    </a>",
"    ]. However, complications such as coronary artery aneurysms, depressed myocardial contractility and heart failure, myocardial infarction, arrhythmias, and peripheral arterial occlusion may develop and lead to significant morbidity and mortality (",
"    <a class=\"graphic graphic_table graphicRef56475 \" href=\"UTD.htm?17/3/17469\">",
"     table 1",
"    </a>",
"    ). Noncardiac complications are also seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The complications of KD are discussed in this review. The epidemiology, etiology, clinical manifestations, diagnosis, treatment, and long-term cardiovascular sequelae of Kawasaki disease are presented separately. Incomplete (atypical) KD and unique features in infants and adults are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=see_link\">",
"     \"Kawasaki disease: Epidemiology and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"     \"Cardiovascular sequelae of Kawasaki disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link\">",
"     \"Incomplete (atypical) Kawasaki disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507746\">",
"    <span class=\"h1\">",
"     SHOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;KD shock syndrome, defined as sustained systolic hypotension (decrease in blood pressure greater than 20 percent from baseline) or clinical signs of poor perfusion, is a potentially life-threatening complication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series from a single institution, 13 of 187 consecutive patients with KD (7 percent) presented with KD shock syndrome between 2003 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/3\">",
"     3",
"    </a>",
"    ]. All patients with KD shock syndrome received fluid resuscitation and seven also received inotropic agents. Patients with shock syndrome were more likely than patients who were hemodynamically stable to have consumptive coagulopathy and cardiac abnormalities including impaired left ventricular systolic function, mitral regurgitation, and coronary artery abnormalities. In addition, patients who presented with shock had higher C-reactive protein levels. They were also less responsive to initial intravenous immunoglobulin therapy, and more commonly required additional treatment of their KD.",
"   </p>",
"   <p>",
"    Multiple organ dysfunction syndrome (MODS) was seen in 8 of 11 patients with KD and shock in another series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5036611\">",
"    <span class=\"h1\">",
"     MACROPHAGE ACTIVATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrophage activation syndrome (MAS, also called secondary hemophagocytic lymphohistiocytosis) is characterized by activation and proliferation of macrophages and T cells. It has been described rarely in children with KD who have persistent and sustained fever after IVIG treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/6-14\">",
"     6-14",
"    </a>",
"    ]. The clinical findings and treatment of MAS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507753\">",
"    <span class=\"h1\">",
"     CARDIAC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major complication of KD is coronary artery (CA) aneurysms, however other cardiac sequelae occur including decreased myocardial contractility, coronary arteritis without aneurysms, mild valvular regurgitation (primarily mitral valve involvement), and pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/15\">",
"     15",
"    </a>",
"    ]. Infants younger than one year of age with KD have the highest risk of developing cardiac complications, including coronary artery aneurysms, despite treatment with IVIG. Acute myocardial infarction is the main cause of death in KD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=see_link&amp;anchor=H2509305#H2509305\">",
"     \"Incomplete (atypical) Kawasaki disease\", section on 'Infants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H242696497#H242696497\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Cardiovascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507760\">",
"    <span class=\"h2\">",
"     Coronary artery abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of CA involvement appears to be present in virtually all children with KD. Serial echocardiography was performed at presentation, and one and five weeks later in a prospective study of 190 patients with KD included in a clinical trial that evaluated the addition of glucocorticoid therapy to conventional immunoglobulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/16\">",
"     16",
"    </a>",
"    ]. In all patients, a maximum coronary artery z score (age- and gender-adjusted deviation from the mean measured as standard deviation units) normalized to body surface area was significantly greater than normal at all time points. In about a quarter of the patients, a maximal z score &ge;2.5 was noted at some time during the course of the disease.",
"   </p>",
"   <p>",
"    In a retrospective review of 100 children treated for KD from a single tertiary center in the United States, 43 percent had a CA abnormality on their initial echocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/17\">",
"     17",
"    </a>",
"    ]. All but five cases had echocardiography performed within 24 hours of treatment for KD. CA ectasia was seen in 31 percent of patients and CA aneurysms in 13 percent. Only 11 percent had CA lesions on their final echocardiogram (ectasia in 6 percent and aneurysm in 5 percent).",
"   </p>",
"   <p>",
"    Coronary artery (CA) aneurysms are a more restrictive category of coronary artery dilation (",
"    <a class=\"graphic graphic_movie graphicRef65317 \" href=\"UTD.htm?35/29/36318\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef53864 \" href=\"UTD.htm?18/43/19134\">",
"     movie 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef76878 \" href=\"UTD.htm?16/54/17262\">",
"     movie 3",
"    </a>",
"    ). The frequencies of aneurysm development and mortality have dramatically decreased as a result of intravenous immune globulin (IVIG) therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/18\">",
"     18",
"    </a>",
"    ]. The acute evaluation, treatment, natural history, and long-term monitoring of CA aneurysms are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H242696505#H242696505\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several clinical findings at presentation are associated with an increased risk of developing CA aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/15,19-27\">",
"     15,19-27",
"    </a>",
"    ]. These risk factors have varied somewhat in different series, although they most consistently include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age younger than one year",
"     </li>",
"     <li>",
"      Male sex",
"     </li>",
"     <li>",
"      Fever &ge;14 days",
"     </li>",
"     <li>",
"      Serum sodium concentration &lt;135",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Hematocrit &lt;35 percent",
"     </li>",
"     <li>",
"      White cell count",
"      <span class=\"nowrap\">",
"       &gt;12,000/mm3",
"      </span>",
"     </li>",
"     <li>",
"      Age older than nine years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Levels of four biomarkers in plasma samples taken before IVIG therapy were examined in a case-control study of 44 patients with KD, 14 with and 33 without CA lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/28\">",
"     28",
"    </a>",
"    ]. A clusterin level of &lt;12",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    was associated with the development of CA lesions. Clusterin (also called apolipoprotein J or complement lysis inhibitor), is a chaperone protein involved in clearance of cellular debris and inhibition of apoptosis.",
"   </p>",
"   <p>",
"    The risk of CA aneurysms is increased in children younger than one year and older than nine years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/29\">",
"     29",
"    </a>",
"    ]. It is not clear whether this increased risk is a result of late diagnosis, which delays administration of IVIG therapy, or an intrinsic susceptibility to coronary artery dilatation in these populations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/30\">",
"     30",
"    </a>",
"    ]. IVIG treatment administered during the first 10 days of illness reduces the prevalence of CA aneurysms fivefold compared with treatment with anything other than IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=see_link&amp;anchor=H26262954#H26262954\">",
"     \"Kawasaki disease: Clinical features and diagnosis\", section on 'Delayed diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, the risk of CA aneurysms varies among ethnic groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report based upon national Kawasaki syndrome surveillance data from 1994 to 2003, Asian and Pacific Islander race and Hispanic ethnicity were associated with an increased risk of CA aneurysms in 3115 children identified with KD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis from the Pediatric Health Information System (PHIS) that identified 4811 patients with KD from 2001 to 2006, the highest rate of CA aneurysms was reported in American Indians, but the number of such patients with KD was small [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/15\">",
"       15",
"      </a>",
"      ]. The second highest rate of CA aneurysms was in Hispanics (5.9 percent), followed by white non-Hispanic patients (3.4 percent), and the lowest rates were seen in black and Asian patients (1.8 percent in both groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic risk factors for CA aneurysms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H242696532#H242696532\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Coronary artery aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of CA aneurysms depends on the size and shape of the aneurysm. The best prognosis is associated with fusiform aneurysms &lt;8 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, giant CA aneurysms, with an internal diameter &gt;8 mm, have the highest risk of morbidity and mortality. Up to one-third of such aneurysms become obstructed, leading to myocardial infarction, arrhythmias, or sudden death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=see_link\">",
"     \"Kawasaki disease: Initial treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link&amp;anchor=H242698581#H242698581\">",
"     \"Cardiovascular sequelae of Kawasaki disease\", section on 'Natural course'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507767\">",
"    <span class=\"h2\">",
"     Depressed myocardial contractility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressed myocardial contractility may be caused by myocarditis, cardiomyopathy, or left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/15\">",
"     15",
"    </a>",
"    ]. Depressed myocardial contractility, occasionally progressing to heart failure, may occur during the acute illness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/33\">",
"     33",
"    </a>",
"    ]. Clinically, this often is manifested by an S3 gallop that may become more prominent with hydration. Normal contractility typically is restored following treatment with IVIG, suggesting that cytokines contribute to the myocardial dysfunction. Nonetheless, a cellular component also contributes; lymphocytic infiltrates or fibrosis are sometimes noted on endomyocardial biopsy even years after the acute illness, especially in children who do not receive IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507774\">",
"    <span class=\"h1\">",
"     NONCORONARY VASCULAR INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular changes also can occur in peripheral and visceral arteries:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral arterial obstruction can lead to ischemia and gangrene; this complication generally accompanies other manifestations of severe disease such as giant coronary artery aneurysms and aneurysms in peripheral arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The vasculitis of KD generally spares visceral vessels, so involvement of other organ systems is unusual. Nonetheless, in rare cases virtually any vascular bed may be affected. Thus, case reports have included KD presenting as a cerebrovascular accident (eg, acute encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/36\">",
"       36",
"      </a>",
"      ], stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/37\">",
"       37",
"      </a>",
"      ]), gastrointestinal obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/38\">",
"       38",
"      </a>",
"      ] or pseudo-obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/39\">",
"       39",
"      </a>",
"      ], or acute abdominal catastrophe [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/40\">",
"       40",
"      </a>",
"      ]. However, consideration must always be given to alternative diagnoses, such as polyarteritis nodosa, in cases with unusual manifestations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507781\">",
"    <span class=\"h1\">",
"     URINARY ABNORMALITIES AND RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of sterile pyuria, urinary abnormalities and renal disease are uncommonly associated with KD. Among the renal complications that have been noted in selected cases are acute interstitial nephritis, mild proteinuria, and acute renal failure (ARF) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. ARF is a rare complication that appears to be a result of different pathologic processes in different patients. Hemolytic-uremic syndrome, immune complex-mediated glomerulonephritis, and acute interstitial nephritis, for example, have each been reported in a handful of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. IVIG may cause acute renal injury as well, especially preparations that use sucrose as a stabilizer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=see_link&amp;anchor=H16#H16\">",
"     \"Intravenous immune globulin: Adverse effects\", section on 'Renal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507788\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with KD may present with a wide variety of gastrointestinal manifestations. A case series from Italy reported 10 children ultimately diagnosed with KD who were treated for acute abdominal catastrophes. They included five patients with gallbladder hydrops and cholestasis, three patients with paralytic ileus, one patient with appendicular vasculitis, and one with hemorrhagic duodenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/40\">",
"     40",
"    </a>",
"    ]. Other reported gastrointestinal complications include intestinal pseudo-obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/45\">",
"     45",
"    </a>",
"    ], intussusception [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/46\">",
"     46",
"    </a>",
"    ], pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], and bile duct stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2507774\">",
"     'Noncoronary vascular involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9203535\">",
"    <span class=\"h1\">",
"     SENSORINEURAL HEARING LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of 40 patients seen between 2005 and 2007 was evaluated for hearing loss within the first 30 days of disease and six months later [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/49\">",
"     49",
"    </a>",
"    ]. Initial evaluation included acoustic immittance measurement and brainstem-evoked response audiometry. Those found to have hearing disability also underwent otoacoustic emissions analysis. Hearing loss was identified in 55 percent of patients within the first 30 days and 30 percent still had hearing loss six months later. Persistent sensorineural hearing loss was associated with delayed use of IVIG and prolonged thrombocytosis, anemia, and an elevated erythrocyte sedimentation rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507795\">",
"    <span class=\"h1\">",
"     BEHAVIORAL CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective study of 65 patients reported an increase in long-term behavioral problems in children following KD when compared with hospital- and sibling-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/50\">",
"     50",
"    </a>",
"    ]. In contrast, an earlier study showed no effects on attention, behavior, or learning in children with KD, but suggested that parents continued to have concerns about their children's health even when there were no apparent sequelae of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16183/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/8/3201?source=see_link\">",
"       \"Patient information: Kawasaki disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2507809\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of Kawasaki disease primarily reflect cardiac sequelae, although noncardiac complications also may occur (",
"      <a class=\"graphic graphic_table graphicRef56475 \" href=\"UTD.htm?17/3/17469\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2507732\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kawasaki disease shock syndrome, defined as sustained systolic hypotension or clinical signs of poor perfusion, is a potentially life-threatening complication. (See",
"      <a class=\"local\" href=\"#H2507746\">",
"       'Shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Macrophage activation syndrome is a rare complication of Kawasaki disease that should be considered in patients with persistent fever after intravenous immune globulin therapy. (See",
"      <a class=\"local\" href=\"#H5036611\">",
"       'Macrophage activation syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"       \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The major complication of Kawasaki disease is coronary artery (CA) aneurysms, however other cardiac sequelae occur including decreased myocardial contractility, coronary arteritis without aneurysms, mild valvular regurgitation (primarily mitral valve involvement), and pericardial effusion. Acute myocardial infarction is the main cause of death in Kawasaki disease. (See",
"      <a class=\"local\" href=\"#H2507753\">",
"       'Cardiac complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=see_link\">",
"       \"Cardiovascular sequelae of Kawasaki disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vascular changes also may occur in peripheral and visceral arteries. Peripheral arterial obstruction can lead to ischemia and gangrene. (See",
"      <a class=\"local\" href=\"#H2507774\">",
"       'Noncoronary vascular involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary abnormalities and renal disease, with the exception of sterile pyuria, are uncommonly associated with Kawasaki disease. (See",
"      <a class=\"local\" href=\"#H2507781\">",
"       'Urinary abnormalities and renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with KD may present with a wide variety of gastrointestinal manifestations including acute abdominal catastrophes. (See",
"      <a class=\"local\" href=\"#H2507788\">",
"       'Gastrointestinal abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sensorineural hearing loss, usually transient and asymptomatic, may be seen following Kawasaki disease. (See",
"      <a class=\"local\" href=\"#H9203535\">",
"       'Sensorineural hearing loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/1\">",
"      Burns JC, Glod&eacute; MP. Kawasaki syndrome. Lancet 2004; 364:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/2\">",
"      Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/3\">",
"      Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123:e783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/4\">",
"      Yim D, Ramsay J, Kothari D, Burgner D. Coronary artery dilatation in toxic shock-like syndrome: the Kawasaki disease shock syndrome. Pediatr Cardiol 2010; 31:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/5\">",
"      Gatterre P, Oualha M, Dupic L, et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med 2012; 38:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/6\">",
"      Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112:e495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/7\">",
"      al-Eid W, al-Jefri A, Bahabri S, al-Mayouf S. Hemophagocytosis complicating Kawasaki disease. Pediatr Hematol Oncol 2000; 17:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/8\">",
"      Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/9\">",
"      Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr 1995; 154:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/10\">",
"      Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010; 32:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/11\">",
"      Hendricks M, Pillay S, Davidson A, et al. Kawasaki disease preceding haemophagocytic lymphohistiocytosis: challenges for developing world practitioners. Pediatr Blood Cancer 2010; 54:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/12\">",
"      Suresh N, Sankar J. Macrophage activation syndrome: a rare complication of incomplete Kawasaki disease. Ann Trop Paediatr 2010; 30:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/13\">",
"      Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatr Hematol Oncol 2010; 27:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/14\">",
"      Simonini G, Pagnini I, Innocenti L, et al. Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease. Pediatr Blood Cancer 2010; 55:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/15\">",
"      Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/16\">",
"      McCrindle BW, Li JS, Minich LL, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation 2007; 116:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/17\">",
"      Baer AZ, Rubin LG, Shapiro CA, et al. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome. Arch Pediatr Adolesc Med 2006; 160:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/18\">",
"      Curtis N, Levin M. Kawasaki disease thirty years on. Curr Opin Pediatr 1998; 10:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/19\">",
"      Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004; 46:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/20\">",
"      Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986; 108:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/21\">",
"      Beiser AS, Takahashi M, Baker AL, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998; 81:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/22\">",
"      Belay ED, Maddox RA, Holman RC, et al. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994-2003. Pediatr Infect Dis J 2006; 25:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/23\">",
"      Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr 2000; 137:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/24\">",
"      Momenah T, Sanatani S, Potts J, et al. Kawasaki disease in the older child. Pediatrics 1998; 102:e7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/25\">",
"      Muta H, Ishii M, Sakaue T, et al. Older age is a risk factor for the development of cardiovascular sequelae in Kawasaki disease. Pediatrics 2004; 114:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/26\">",
"      Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/27\">",
"      Manlhiot C, Yeung RS, Clarizia NA, et al. Kawasaki disease at the extremes of the age spectrum. Pediatrics 2009; 124:e410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/28\">",
"      Yu HR, Kuo HC, Huang EY, et al. Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with Kawasaki disease. Pediatr Cardiol 2010; 31:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/29\">",
"      Song D, Yeo Y, Ha K, et al. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr 2009; 168:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/30\">",
"      Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr 2009; 168:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/31\">",
"      Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/32\">",
"      Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/33\">",
"      Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Circulation 1989; 79:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/34\">",
"      Yonesaka S, Takahashi T, Matubara T, et al. Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequelae and regional wall motion abnormalities of the left ventricle. Jpn Circ J 1992; 56:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/35\">",
"      Tomita S, Chung K, Mas M, et al. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis 1992; 14:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/36\">",
"      Tabarki B, Mahdhaoui A, Selmi H, et al. Kawasaki disease with predominant central nervous system involvement. Pediatr Neurol 2001; 25:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/37\">",
"      Suda K, Matsumura M, Ohta S. Kawasaki disease complicated by cerebral infarction. Cardiol Young 2003; 13:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/38\">",
"      Mele T, Evans M. Intestinal obstruction as a complication of Kawasaki disease. J Pediatr Surg 1996; 31:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/39\">",
"      Akikusa JD, Laxer RM, Friedman JN. Intestinal pseudoobstruction in Kawasaki disease. Pediatrics 2004; 113:e504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/40\">",
"      Zulian F, Falcini F, Zancan L, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 2003; 142:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/41\">",
"      Veiga PA, Pieroni D, Baier W, Feld LG. Association of Kawasaki disease and interstitial nephritis. Pediatr Nephrol 1992; 6:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/42\">",
"      Ferriero DM, Wolfsdorf JI. Hemolytic uremic syndrome associated with Kawasaki disease. Pediatrics 1981; 68:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/43\">",
"      Salcedo JR, Greenberg L, Kapur S. Renal histology of mucocutaneous lymph node syndrome (Kawasaki disease). Clin Nephrol 1988; 29:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/44\">",
"      Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum 2004; 34:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/45\">",
"      Lin YL, Chang TJ, Lu KC, et al. Surgical treatment of Kawasaki disease with intestinal pseudo-obstruction. Indian J Pediatr 2011; 78:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/46\">",
"      Hussain RN, Ruiz G. Kawasaki disease presenting with intussusception: a case report. Ital J Pediatr 2010; 36:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/47\">",
"      Prokic D, Ristic G, Paunovic Z, Pasic S. Pancreatitis and atypical Kawasaki disease. Pediatr Rheumatol Online J 2010; 8:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/48\">",
"      Cherry R, Naon H, Cohen H, et al. Common bile duct stenosis and pancreatitis in Kawasaki disease: two cases and a review of the literature. Pediatr Infect Dis J 2010; 29:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/49\">",
"      Magalh&atilde;es CM, Magalh&atilde;es Alves NR, Oliveira KM, et al. Sensorineural hearing loss: an underdiagnosed complication of Kawasaki disease. J Clin Rheumatol 2010; 16:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/50\">",
"      Carlton-Conway D, Ahluwalia R, Henry L, et al. Behaviour sequelae following acute Kawasaki disease. BMC Pediatr 2005; 5:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16183/abstract/51\">",
"      Baker AL, Gauvreau K, Newburger JW, et al. Physical and psychosocial health in children who have had Kawasaki disease. Pediatrics 2003; 111:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15688 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16183=[""].join("\n");
var outline_f15_51_16183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2507809\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507732\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507746\">",
"      SHOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5036611\">",
"      MACROPHAGE ACTIVATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507753\">",
"      CARDIAC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2507760\">",
"      Coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2507767\">",
"      Depressed myocardial contractility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507774\">",
"      NONCORONARY VASCULAR INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507781\">",
"      URINARY ABNORMALITIES AND RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507788\">",
"      GASTROINTESTINAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9203535\">",
"      SENSORINEURAL HEARING LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507795\">",
"      BEHAVIORAL CHANGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2507809\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/15688\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15688|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/29/36318\" title=\"movie 1\">",
"      Ascending aorta in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/43/19134\" title=\"movie 2\">",
"      Left coronary artery in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?16/54/17262\" title=\"movie 3\">",
"      Right coronary artery in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/15688|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/3/17469\" title=\"table 1\">",
"      Complications of Kawasaki disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30826?source=related_link\">",
"      Cardiovascular sequelae of Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11814?source=related_link\">",
"      Incomplete (atypical) Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/32/38409?source=related_link\">",
"      Intravenous immune globulin: Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/19/11575?source=related_link\">",
"      Kawasaki disease: Epidemiology and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42025?source=related_link\">",
"      Kawasaki disease: Initial treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/8/3201?source=related_link\">",
"      Patient information: Kawasaki disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16184="Treatment and prognosis of Chagas heart disease";
var content_f15_51_16184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of Chagas heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     J Antonio Marin-Neto, MD, PhD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Benedito C Maciel, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Marcus V Sim&otilde;es, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Andre Schmidt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16184/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/51/16184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20890155\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chagas disease (CD) is caused by Trypanosoma cruzi, a protozoan parasite that can cause acute myopericarditis as well as chronic fibrosing myocarditis. Chagas myocarditis is the most common cause of non-ischemic cardiomyopathy in Latin America [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and prognosis of Chagas heart disease will be reviewed here. Other issues related to CD, including clinical manifestations and diagnosis of Chagas heart disease and noncardiac manifestations, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link\">",
"     \"Chagas disease: Natural history and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=see_link\">",
"     \"Pathology and pathogenesis of Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=see_link\">",
"     \"Gastrointestinal Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372250898\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20890364\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of Chagas disease has been divided into acute and chronic phases. Cardiac involvement and prognosis in the acute phase of T. cruzi is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=see_link\">",
"     \"Chagas disease: Natural history and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indeterminate form of chronic T. cruzi has been defined as a phase of chronic T. cruzi infection in which anti-T. cruzi antibodies are present but no signs or symptoms of Chagas cardiomyopathy or gastrointestinal involvement are identified. Various criteria have been proposed to define the indeterminate form, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=see_link&amp;anchor=H16764838#H16764838\">",
"     \"Clinical manifestations and diagnosis of Chagas heart disease\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    About one-third to one-half of patients with the indeterminate form develops cardiomyopathy after a latent period ranging from 5 to 30 years. Chronic Chagas disease cardiomyopathy (CCC) is a cause of heart failure, cardiac arrhythmias and thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20890421\">",
"    <span class=\"h2\">",
"     Prognosis of CCC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality associated with the chronic phase of CD is almost exclusively due to cardiovascular involvement. Death is sudden in 55 to 65 percent, due to progressive heart failure in 25 to 30 percent, and stroke in 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/2\">",
"     2",
"    </a>",
"    ]. Comparative data from observational studies suggest that the mortality rate for patients presenting with heart failure due to CD is also higher than the mortality due to other etiologies of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In young patients with segmental wall motion abnormalities without heart failure, sudden death occurs more frequently than death from heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major risk factors for mortality in patients with Chagas cardiomyopathy are clinical heart failure, evidence of left ventricular dilatation or systolic dysfunction, and non-sustained ventricular tachycardia (NSVT). A risk score (Rassi score) for predicting mortality was developed in 424 patients with Chagas cardiomyopathy based on simple clinical and laboratory evaluation and was validated in a separate cohort of 153 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/6\">",
"     6",
"    </a>",
"    ]. In the initial cohort, the mean patient age was 47 years and there were 130 deaths (31 percent) during a mean follow-up of 7.9 years. Death was sudden in 71 percent, due to progressive heart failure in 19 percent and due to thromboembolism in 10 percent. Multivariate analysis identified six independent predictors of mortality, and each predictor was assigned a point value:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      NYHA class",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      (5 points)",
"     </li>",
"     <li>",
"      Cardiomegaly on chest X-ray (5 points)",
"     </li>",
"     <li>",
"      Left ventricular systolic dysfunction on echocardiogram (3 points)",
"     </li>",
"     <li>",
"      Nonsustained ventricular tachycardia (NSVT) on Holter monitoring (3 points)",
"     </li>",
"     <li>",
"      Low QRS voltage (2 points)",
"     </li>",
"     <li>",
"      Male gender (2 points)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ten-year mortality in patients with 12 to 20 points was 84 to 85 percent; for patients with 7 to 11 points it was 37 to 44 percent and for patients with 0 to 6 points it was 9 to 10 percent. The combination of left ventricular systolic dysfunction and NSVT was associated with particularly high risk (15.1 fold increased risk of death) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/6\">",
"     6",
"    </a>",
"    ]. The presence of NSVT alone was associated with a 2.15-fold increased risk of death.",
"   </p>",
"   <p>",
"    A systematic review identified predictors of mortality in chronic CD from 12 observational studies with 4277 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/7\">",
"     7",
"    </a>",
"    ]. Although most studies focused on patients with established CCC, four of the studies included some patients with the indeterminate form (normal ECG and normal chest x-ray).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common and consistent independent risk factor for death was impaired left ventricular function as identified by echocardiography or ventriculography. Evidence of left ventricular dysfunction included presence of reduced left ventricular ejection fraction, left ventricular aneurysm, regional or global wall motion abnormality, increased left ventricular end systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      end diastolic dimension, increased left ventricular end-diastolic volume or volume index, and M-mode increased E-point septal separation.",
"     </li>",
"     <li>",
"      Other independent risk factors for mortality were symptoms (dyspnea, heart failure, or New York Heart Association functional class",
"      <span class=\"nowrap\">",
"       III/IV)",
"      </span>",
"      and cardiomegaly on chest radiography.",
"     </li>",
"     <li>",
"      Sinus tachycardia was associated with increased mortality in two studies. Although various other ECG abnormalities were associated with mortality in individual studies, no single finding was associated with mortality in greater than one study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Male gender was associated with worse prognosis in the study above that defined the Rassi score [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/6\">",
"     6",
"    </a>",
"    ], but was not an independent predictor in other studies. Similarly, advanced age was associated with worse prognosis in two studies, but not others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251508\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251516\">",
"    <span class=\"h2\">",
"     Acute and indeterminate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antitrypanosomal drugs in acute and indeterminate disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link&amp;anchor=H107060876#H107060876\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\", section on 'Acute Chagas disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=see_link\">",
"     \"Antitrypanosomal drug therapy for Chagas disease\"",
"    </a>",
"    .) Summarized briefly, antitrypanosomal therapy is recommended to treat acute disease, irrespective of the transmission mechanism, and reactivation of the infection in chronic cases. Although data are limited, most experts recommend antitrypanosomal therapy to treat individuals with the indeterminate form of Chagas disease (especially children).",
"   </p>",
"   <p>",
"    Pericardial effusion is common in acute CD and occasionally complicated by tamponade which is treated by pericardiocentesis, as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link\">",
"     \"Cardiac tamponade\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251524\">",
"    <span class=\"h2\">",
"     Chronic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antitrypanosomal drugs is limited in treating chronic disease since such therapy will not reverse existing pathology in advanced Chagas cardiac disease. In patients with advanced heart disease, the focus of management is supportive care for heart failure, arrhythmia, and thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251532\">",
"    <span class=\"h3\">",
"     T.cruzi infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antitrypanosomal therapy in chronic CD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=see_link&amp;anchor=H107060907#H107060907\">",
"     \"Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts\", section on 'Antitrypanosomal therapy'",
"    </a>",
"    .) Summarized briefly, data on treatment of chronic CD are limited and antitrypanosomal therapy is unlikely to benefit those with severe heart disease.",
"   </p>",
"   <p>",
"    Limited evidence suggests that antitrypanosomal therapy may be beneficial in some patients with chronic CD. An unblinded, nonrandomized trial in 566 patients with chronic CD and without heart failure found that benznidazole treatment was associated with less frequent clinical progression of CD (4 versus 14 percent) compared to no treatment over median 9.8 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/8\">",
"     8",
"    </a>",
"    ]. Fewer treated patients developed electrocardiographic abnormalities (5 versus 16 percent).",
"   </p>",
"   <p>",
"    The results of a large multicenter randomized controlled trial of trypanocidal therapy in patients with Chagas heart disease are not expected before 2014 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/9\">",
"     9",
"    </a>",
"    ]. In the interim, we suggest antitrypanosomal therapy to treat patients with chronic infection up to 50 years of age including those with evidence of early Chagas heart disease (eg, ECG abnormalities without heart failure) but",
"    <strong>",
"     not",
"    </strong>",
"    in those with advanced Chagas cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/10\">",
"     10",
"    </a>",
"    ]. The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    as an antitrypanosomal agent is unknown. (See",
"    <a class=\"local\" href=\"#H372251597\">",
"     'Antiarrhythmic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251539\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure due to Chagas disease is treated as for heart failure due to other causes as discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251547\">",
"    <span class=\"h4\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the efficacy of heart failure therapies in the setting of Chagas disease. In a trial of 42 patients randomized to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    or placebo in addition to ACE inhibitor (or ARB) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    treatment, carvedilol plus ACE inhibitor was generally tolerated with associated improvements in Framingham heart failure score and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/11\">",
"     11",
"    </a>",
"    ]. However, because all therapies employed in CD patients are empirically extrapolated from trials performed in patients with heart failure of other etiologies, the real benefit associated to each class of drugs remains to be demonstrated, both in terms of morbidity and mortality. This is especially relevant in the case of beta-blockers, since CD patients often have bradycardia that may limit their use, particularly with concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251554\">",
"    <span class=\"h4\">",
"     Other HF therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) has been empirically applied to patients with CCC who have predominantly right bundle branch block, although most patients in the CRT trials had left bundle branch block. The utility of CRT in patients with CCC with right bundle branch block remains to be determined.",
"   </p>",
"   <p>",
"    Cardiac transplantation has been successful in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. One study of 117 patients with CD who underwent transplantation reported survival at 1, 4, 8, and 12 years after transplantation as 71, 57, 55, and 46 percent, respectively. These observational data showed that the survival of patients with CD was better than the survival of patients with ischemic heart disease or idiopathic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/13\">",
"     13",
"    </a>",
"    ]. Causes of death following transplantation included infection, rejection, and neoplasm (10, 10 and 4 percent, respectively); reactivation of Trypanosoma cruzi infection was the cause of death in only two patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Palliative procedures such as dynamic cardiomyoplasty and partial ventriculectomy have been performed in small groups of patients with intractable heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/14\">",
"     14",
"    </a>",
"    ]. The efficacy of these interventions with respect to long-term improvement in quality of life and survival has not been defined and these surgical approaches have been abandoned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=see_link&amp;anchor=H4#H4\">",
"     \"Surgical management of heart failure\", section on 'Left ventricular reconstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of intracoronary injection of autologous bone marrow derived mononuclear cells (BMNC) as compared to placebo was evaluated in a randomized trial enrolling 234 patients with CCC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/15\">",
"     15",
"    </a>",
"    ]. There were no significant differences in the change in LVEF, functional status, and brain natriuretic peptide levels at 6 and 12 months. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251561\">",
"    <span class=\"h3\">",
"     Bradyarrhythmias and heart block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with second- or third-degree atrioventricular block or symptomatic sinus node dysfunction require permanent cardiac pacing. Indications for permanent pacing are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251568\">",
"    <span class=\"h3\">",
"     Ventricular arrhythmia and SCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach for management of arrhythmia due to Chagas heart disease is uncertain. Potentially beneficial treatment tools include heart failure therapy, antiarrhythmic drugs, radiofrequency catheter ablation, implantable cardioverter-defibrillator device (ICD) placement, and surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251576\">",
"    <span class=\"h4\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in treating patients with CCC at risk for arrhythmia is optimization of medical therapy for HF (including beta blockers) since this may improve survival and reduce ventricular arrhythmias.",
"   </p>",
"   <p>",
"    Appropriate measures to reduce the risk of sudden cardiac arrest (SCA) in patients with CCC are uncertain due to paucity of data. A separate concern is that widespread use of ICDs would be hampered by socioeconomic limitations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      for patients with CCC who survive an episode of SCA or have sustained ventricular tachycardia not treated with ICDs (due to physician or patient preference or because they are not candidates for an ICD). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Empiric pharmacologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest an ICD for patients with CCC who survive an episode of SCA or have sustained ventricular tachycardia, particularly if the patient has already been treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      beta blocker therapy.",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      plus beta blocker therapy to reduce shocks in patients with CCC treated with ICDs. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter ablation is suggested for patients with CCC with symptomatic monomorphic sustained VT (including VT terminated by an ICD) that recurs despite antiarrhythmic drug therapy or when antiarrhythmic drugs are not tolerated or not desired. Other recommendations for catheter ablation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"       \"Catheter ablation for ventricular arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      plus beta blocker therapy for patients with CCC with an LVEF &le;35 percent AND a Rassi score of &gt;10 OR nonsustained VT on Holter. &nbsp;",
"     </li>",
"     <li>",
"      For patients with CCC with an LVEF &le;35 percent, and a Rassi score of 10 or more and non-sustained VT on Holter, and a reasonable likelihood of survival of at least one year, ICD implantation is suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251583\">",
"    <span class=\"h4\">",
"     CCC-specific evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the safety and efficacy of antiarrhythmic drug, device, ablation, and surgical treatment in patients with CCC. Thus, the above recommendations are largely based upon data on patients at risk for SCA due to heart disease other than CCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251590\">",
"    <span class=\"h5\">",
"     ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of patients with CCC treated with ICDs have so far yielded mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of ICD use for secondary prevention of SCD, 90 patients with CD with sustained VT or VF underwent ICD implantation and were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/16\">",
"       16",
"      </a>",
"      ]. Baseline mean left ventricular ejection fraction was 47 percent. Sixty-four percent of patients received an appropriate shock during mean follow-up of two years. Mortality was 18, 27, 40, 50, and 73 percent at one, two, three, four, and, five-year follow-up. Nearly all deaths were due to pump failure. The only independent predictor of mortality was number of shocks per patient per 30 days.",
"      <br/>",
"      <br/>",
"      Adverse outcomes in patients who have received ICDs have raised concern that deterioration of LV function may be associated with ICD insertion in patients receiving multiple frequent shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somewhat better outcomes were observed in two later series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], but have also indicated that device implantation for secondary prevention is associated with high rates of appropriate and inappropriate shocks as illustrated by the two later larger studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Results at mean one-year follow-up were reported for a series of 148 patients with CD undergoing ICD implantation (92 percent for secondary prevention) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/18\">",
"       18",
"      </a>",
"      ]. The baseline mean left ventricular ejection fraction was 40 percent. An appropriate shock was administered to 42.5 percent of patients during mean follow-up of one year. Mortality was 10 percent (15 patients) including three deaths from heart failure and four SCD. Age &gt;65 years and left ventricular ejection fraction &lt;30 percent were independent predictors of mortality.",
"     </li>",
"     <li>",
"      116 patients with CD undergoing ICD implantation for secondary prevention were followed for a mean of 45 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/19\">",
"       19",
"      </a>",
"      ]. The baseline mean left ventricular ejection fraction was 42 percent. Fifty percent of patients had appropriate shocks and 11 percent had inappropriate ICD therapy. The annual mortality rate was 7 percent, with 45 percent of deaths caused by heart failure with no sudden deaths. Survival was worse in patients with more severe heart failure symptoms (New York Heart Association functional class III), lower left ventricular ejection fraction, and more frequent right ventricular pacing.",
"      <br/>",
"      <br/>",
"      Of note, 17 patients who received multiple appropriate ICD therapies, including 11 patients with electrical storm, underwent radiofrequency catheter ablation. The authors postulated that use of radiofrequency catheter ablation may have improved survival in these patients with CD treated with ICDs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the impact of ICD implantation on survival remains uncertain, controlled trials of such therapy in CCC are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251597\">",
"    <span class=\"h5\">",
"     Antiarrhythmic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations on antiarrhythmic therapy in patients with CCC are based upon extrapolation of data from other patient populations and limited observational data in patients with CCC. Case series of patients with CCC suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    suppresses asymptomatic ventricular arrhythmias but its effect on clinical outcomes has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There is no conclusive evidence that pharmacologic treatment improves survival in patients with CCC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/22\">",
"     22",
"    </a>",
"    ]. Use of amiodarone in patients with CCC is based upon evidence that it improves survival free of cardiac arrest or ICD shocks in patients with other types of heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Empiric pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observations from in vitro and animal studies and a case report suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may have an antitrypanosomal effect, although its efficacy as an antiparasitic agent has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/23\">",
"     23",
"    </a>",
"    ]. Also, as noted above, antiparasitic treatment is unlikely to affect established severe CCC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251604\">",
"    <span class=\"h5\">",
"     Ablation and surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have suggested that catheter ablation can reduce the risk of recurrent ventricular tachycardia in patients with CCC and may contribute to improved survival in patients receiving ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/19,24-26\">",
"     19,24-26",
"    </a>",
"    ]. As for other patients with structural heart disease with frequent episodes of VT and ICD shocks, catheter ablation is recommended as adjunctive therapy in patients with an ICD who have frequent episodes of VT and ICD shocks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older case reports suggested that some patients with CCC with recurrent sustained ventricular tachycardia may benefit from surgical excision of arrhythmogenic sites following electrophysiologic mapping adjacent to ventricular aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], similar to the limited experience in patients with ischemic heart disease. However, the risks and benefits of such surgery is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=see_link\">",
"     \"Surgery for ventricular tachyarrhythmias\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251611\">",
"    <span class=\"h4\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 Latin American guidelines for CCC do not recommend ICD therapy for primary prevention of sudden cardiac arrest (SCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/30\">",
"     30",
"    </a>",
"    ]. For secondary prevention, the guidelines note that pharmacologic therapy should be an adjunct to ICD in patients with sustained ventricular tachycardia and LVEF &lt;35 percent. For patients with well-tolerated sustained ventricular tachycardia with preserved LVEF, the guidelines suggest ICD implantation as the safest option, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and ablation as other options. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2011 Latin American guidelines include recommendations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    similar to those we suggest above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    guidelines for device-based therapy of cardiac rhythm abnormalities recommend an ICD for secondary prevention in patients who are survivors of SCA due to ventricular fibrillation or who have spontaneous sustained VT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/31\">",
"     31",
"    </a>",
"    ]. These guidelines also recommend an ICD for primary prevention in patients with nonischemic dilated cardiomyopathy with an LVEF &le;35 percent and NYHA functional class II or III. However, these guidelines include scant discussion of treatment of CCC. They note only that ICD implantation is reasonable for patients with Chagas disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for management of ventricular arrhythmias include discussion of pharmacologic therapy and adjunctive therapy (including drug therapy and ablation) in patients treated with ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16184/abstract/32\">",
"     32",
"    </a>",
"    ]. However, these guidelines include limited discussion of CCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251618\">",
"    <span class=\"h3\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to anticoagulation for prevention of thromboembolism in patients with heart failure are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H372251625\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of chronic Chagas heart disease is tailored to the nature of individual cardiac manifestations.",
"     </li>",
"     <li>",
"      The most important prognostic factor is the degree of left ventricular myocardial dysfunction. The mortality rate for patients presenting with heart failure due to CD seems to be higher in comparison to mortality due to other etiologies of heart failure.",
"     </li>",
"     <li>",
"      Heart failure due to Chagas disease is generally treated as heart failure due to other causes as discussed in detail separately, but there are some specific caveats. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest antitrypanosomal therapy to treat patients with chronic infection up to 50 years of age including those with evidence of early Chagas heart disease (eg, ECG abnormalities or LV dysfunction without heart failure) but",
"      <strong>",
"       not",
"      </strong>",
"      in those with advanced Chagas cardiomyopathy.",
"     </li>",
"     <li>",
"      Antitrypanosomal therapy is probably not effective for reversal of established myocardial pathology, and it is not known if it can slow the progression of cardiac damage. Thus, in patients with advanced Chagas cardiomyopathy, the focus of management is supportive care for heart failure, arrhythmia, and thromboembolism.",
"     </li>",
"     <li>",
"      Treatment of patients with Chagas disease at risk for sudden cardiac death is controversial. Although implantable cardioverter-defibrillator (ICD) therapy has been empirically used for primary and secondary prevention of sudden cardiac arrest (SCA), there may be potential adverse effects of pacing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ICD therapy on pump function.",
"     </li>",
"     <li>",
"      For secondary prevention of SCA or sustained ventricular tachycardia (see",
"      <a class=\"local\" href=\"#H372251576\">",
"       'Our approach'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      for patients with CCC who survive an episode of SCA or have sustained ventricular tachycardia not treated with ICDs (due to physician or patient preference or because they are not candidates for an ICD) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest an ICD for patients with CCC who survive an episode of SCA or have sustained ventricular tachycardia, particularly if the patient has already been treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      beta blocker therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      plus beta blocker therapy to reduce shocks in patients with CCC treated with ICDs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For primary prevention of SCA or sustained ventricular tachycardia (See",
"      <a class=\"local\" href=\"#H372251576\">",
"       'Our approach'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      plus beta blocker therapy for patients with CCC with an LVEF &le;35 percent AND a Rassi score of &gt;10",
"      <strong>",
"       or",
"      </strong>",
"      nonsustained VT on Holter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      For patients with CCC with an LVEF &le;35 percent, and a Rassi score of &gt;10 and non-sustained VT on Holter, and a reasonable likelihood of survival of at least one year, ICD implantation is suggested (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/1\">",
"      Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009; 104 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/2\">",
"      Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol 2001; 76:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/3\">",
"      Freitas HF, Chizzola PR, Paes AT, et al. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease. Int J Cardiol 2005; 102:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/4\">",
"      Issa VS, Amaral AF, Cruz FD, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail 2010; 3:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/5\">",
"      Espinosa R, Carrasco HA, Belandria F, et al. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973-1983). Int J Cardiol 1985; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/6\">",
"      Rassi A Jr, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 2006; 355:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/7\">",
"      Rassi A Jr, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease: a systematic review of observational studies. Circulation 2007; 115:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/8\">",
"      Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/9\">",
"      Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/10\">",
"      Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/11\">",
"      Botoni FA, Poole-Wilson PA, Ribeiro AL, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J 2007; 153:544.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/12\">",
"      Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg 1996; 61:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/13\">",
"      Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. First Guidelines Group for Heart Transplantation of the Brazilian Society of Cardiology. Ann Thorac Surg 2001; 71:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/14\">",
"      Moreira LF, Stolf NA, Braile DM, Jatene AD. Dynamic cardiomyoplasty in South America. Ann Thorac Surg 1996; 61:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/15\">",
"      Ribeiro Dos Santos R, Rassi S, Feitosa G, et al. Cell therapy in Chagas cardiomyopathy (Chagas arm of the multicenter randomized trial of cell therapy in cardiopathies study): a multicenter randomized trial. Circulation 2012; 125:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/16\">",
"      Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol 2007; 18:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/17\">",
"      Rassi A Jr. Implantable cardioverter-defibrillators in patients with Chagas heart disease: misperceptions, many questions and the urgent need for a randomized clinical trial. J Cardiovasc Electrophysiol 2007; 18:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/18\">",
"      di Toro D, Muratore C, Aguinaga L, et al. Predictors of all-cause 1-year mortality in implantable cardioverter defibrillator patients with chronic Chagas' cardiomyopathy. Pacing Clin Electrophysiol 2011; 34:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/19\">",
"      Martinelli M, de Siqueira SF, Sternick EB, et al. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease. Am J Cardiol 2012; 110:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/20\">",
"      Haedo AH, Chiale PA, Bandieri JD, et al. Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms. J Am Coll Cardiol 1986; 7:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/21\">",
"      Rosenbaum M, Posse R, Sgammini H, et al. [Comparative multicenter clinical study of flecainide and amiodarone in the treatment of ventricular arrhythmias associated with chronic Chagas cardiopathy]. Arch Inst Cardiol Mex 1987; 57:325.",
"     </a>",
"    </li>",
"    <li>",
"     Marin-Neto JA, Rassi JR A, Maciel BC, et al. Chagas heart disease. In: Evidence-Based Cardiology, 3rd ed, Yusuf S, Cairns J, Camm J, et al.  (Eds), 2010. p.823.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/23\">",
"      Benaim G, Paniz Mondolfi AE. The emerging role of amiodarone and dronedarone in Chagas disease. Nat Rev Cardiol 2012; 9:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/24\">",
"      de Paola AA, Melo WD, T&aacute;vora MZ, Martinez EE. Angiographic and electrophysiological substrates for ventricular tachycardia mapping through the coronary veins. Heart 1998; 79:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/25\">",
"      Sosa E, Scanavacca M, D'Avila A, et al. Endocardial and epicardial ablation guided by nonsurgical transthoracic epicardial mapping to treat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol 1998; 9:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/26\">",
"      de Paola AA, Balb&atilde;o CE, Castiglioni ML, et al. [Radioisotopic mapping of the arrhythmogenic focus in patients with chronic chagasic cardiomyopathy and sustained ventricular tachycardia]. Arq Bras Cardiol 1993; 60:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/27\">",
"      Milei J, Pesce R, Valero E, et al. Electrophysiologic-structural correlations in chagasic aneurysms causing malignant arrhythmias. Int J Cardiol 1991; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/28\">",
"      Castagnino HE, Cicco JA, Coniglio J, et al. [Chagasic ventricular aneurysm with ventricular tachycardia operated on with good results]. Medicina (B Aires) 1975; 35:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/29\">",
"      Iturralde P, Barrag&aacute;n R, Araya V, et al. [Surgical resection of a focus of ventricular tachycardia guided by endocardial and epicardial mapping]. Arch Inst Cardiol Mex 1992; 62:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/30\">",
"      Andrade JP, Marin Neto JA, Paola AA, et al. I Latin American Guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol 2011; 96:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/31\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16184/abstract/32\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4925 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16184=[""].join("\n");
var outline_f15_51_16184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H372251625\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20890155\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H372250898\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20890364\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20890421\">",
"      Prognosis of CCC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H372251508\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372251516\">",
"      Acute and indeterminate disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H372251524\">",
"      Chronic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372251532\">",
"      - T.cruzi infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372251539\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251547\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251554\">",
"      Other HF therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372251561\">",
"      - Bradyarrhythmias and heart block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372251568\">",
"      - Ventricular arrhythmia and SCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251576\">",
"      Our approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251583\">",
"      CCC-specific evidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251590\">",
"      - ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251597\">",
"      - Antiarrhythmic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251604\">",
"      - Ablation and surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H372251611\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H372251618\">",
"      - Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H372251625\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14356?source=related_link\">",
"      Antitrypanosomal drug therapy for Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2969?source=related_link\">",
"      Chagas disease: Management of acute disease, early chronic disease, and disease in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/551?source=related_link\">",
"      Chagas disease: Natural history and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14266?source=related_link\">",
"      Clinical manifestations and diagnosis of Chagas heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16742?source=related_link\">",
"      Gastrointestinal Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19975?source=related_link\">",
"      Pathology and pathogenesis of Chagas disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/44/34503?source=related_link\">",
"      Surgery for ventricular tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35143?source=related_link\">",
"      Surgical management of heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16185="Treatment of hepatitis B in the HIV-infected patient";
var content_f15_51_16185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hepatitis B in the HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16185/contributors\">",
"     Barbara H McGovern, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16185/contributors\">",
"     Kenneth E Sherman, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16185/contributors\">",
"     David Thomas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16185/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/51/16185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The era of potent antiretroviral therapy (ART) has led to declining rates of opportunistic infections and a new focus on other leading causes of morbidity, such as end-stage liver disease (ESLD) secondary to chronic hepatitis B virus (HBV) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/1\">",
"     1",
"    </a>",
"    ]. The treatment and prevention of hepatitis B has taken on great significance in light of the negative impact HIV has on the natural history of chronic hepatitis B infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the treatment of chronic HBV infection in the HIV-infected host. The epidemiology, natural history, clinical manifestations, diagnosis, evaluation for treatment candidacy, and prevention of infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44020?source=see_link\">",
"     \"Evaluation of chronic hepatitis B virus infection in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6119?source=see_link\">",
"     \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37223?source=see_link\">",
"     \"Antiviral medications for the treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7931840\">",
"    <span class=\"h1\">",
"     RATIONALE TO TREAT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25695747\">",
"    <span class=\"h2\">",
"     Patients with HBV alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatitis B virus (HBV) infection in HIV-seronegative patients is associated with the development of cirrhosis, end-stage liver disease (ESLD), and hepatocellular carcinoma (HCC); the risk of these complications increases with rising levels of HBV DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25695762\">",
"    <span class=\"h2\">",
"     Patients with HIV and HBV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients, there is rationale to treat both viral infections.",
"   </p>",
"   <p>",
"    Observational data from the United States and Europe suggest that",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients may have faster rates of fibrosis progression and an increased risk of cirrhosis, ESLD, and HCC than patients with HBV infection alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. HCC also occurs at an earlier age among patients who are HIV-infected compared with HIV-seronegative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/11\">",
"     11",
"    </a>",
"    ]. Of note,",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients also have higher levels of HBV DNA compared with patients with HBV alone, which may have implications for the natural history of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\", section on 'HIV and natural history of HBV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among coinfected patients, untreated HIV is also associated with an increased risk of a liver-related death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/13\">",
"     13",
"    </a>",
"    ]. Although the mechanism by which HIV infection may accelerate liver disease progression is unknown, a direct interaction between HIV and stellate cells of the liver, which play a key role in fibrogenesis, has been suggested by histopathologic studies in HIV-infected patients with hepatitis C infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, HIV-associated immunosuppression has an adverse effect on HBV-related disease; in coinfected individuals, the risk of liver-related mortality and HCC increases as the CD4 cell count declines [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, treatment of both infections appears to be safer than treating HIV alone. When antiretroviral medications, which do not have any activity against HBV, are selected for treatment of HIV, immunologic recovery secondary to HIV suppression can lead to significant liver injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H42#H42\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Case one, young Asian with active replication'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link&amp;anchor=H14#H14\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\", section on 'HBV and immune reconstitution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of both infections is facilitated by the availability of several medications that have dual activity against HIV and HBV, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    . Thus, the HIV treatment guidelines recommend treatment for HIV and HBV regardless of CD4 cell count and regardless of the presence or absence of liver disease. (See",
"    <a class=\"local\" href=\"#H1960787\">",
"     'General principles to guide management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H912788\">",
"    <span class=\"h1\">",
"     GOALS OF HEPATITIS B VIRUS THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the optimal goal of treatment is long-lasting control of hepatitis B virus (HBV) infection, as indicated by hepatitis B surface antigen (HBsAg) seroconversion (ie, loss of HBsAg and gain of hepatitis B surface antibody [HBsAb]), the vast majority of",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients do not reach this endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/15\">",
"     15",
"    </a>",
"    ]. This is also true of patients with chronic HBV infection who are HIV-seronegative.",
"   </p>",
"   <p>",
"    Other primary treatment goals include viral suppression, improving liver histology, and delaying progression of end-stage liver disease and the onset of hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/16\">",
"     16",
"    </a>",
"    ]. Observational data with long-term follow-up of HBV treatment trials in HIV-seronegative patients suggest that viral suppression is associated with slower fibrosis progression rates and decreased liver-related morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Similarly, observational data suggest that antiretroviral therapy, which contains an HBV active agent, is associated with slower rates of fibrosis progression and lower rates of liver-related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In addition, long-term HBV DNA suppression is feasible with current therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among hepatitis B &ldquo;e&rdquo; antigen (HBeAg)-seropositive patients, another treatment goal is HBeAg seroconversion (ie, loss of HBeAg and gain of anti-HBe), which is associated with a transition to declining levels of viremia and inactive liver disease in most patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring of the",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfected patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6119?source=see_link\">",
"     \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H913227\">",
"    <span class=\"h1\">",
"     ANTIVIRAL AGENTS FOR HEPATITIS B VIRUS INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antiviral agents, which fall into the nucleotide or nucleoside reverse transcriptase inhibitor (NRTI) category of drugs, are available for the treatment of hepatitis B virus (HBV) infection. In contrast to HIV treatment, which requires three potent antiretroviral medications, HBV therapy usually utilizes one agent, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    , which are considered first-line therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link&amp;anchor=H11#H11\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\", section on 'Resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of these antiviral agents have dual therapeutic activity against HIV and HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       Emtricitabine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"     </li>",
"     <li>",
"      Truvada (a coformulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is considered a first-line agent for the treatment of HBV infection, regardless of HIV status. Tenofovir is also a first-line agent for the treatment of HIV infection. No drug resistance has been reported to date with tenofovir and it is also active against",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    -resistant virus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/25\">",
"     25",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is another first-line agent for the treatment of HBV in the HIV-uninfected patient. However, its use in the",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patient is complicated by concerns regarding HIV drug resistance. In addition, entecavir&rsquo;s efficacy is reduced in patients with lamivudine drug resistance. (See",
"    <a class=\"local\" href=\"#H1960921\">",
"     'HIV drug resistance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1960825\">",
"     'HBV drug resistance in treatment-naive patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Agents with activity against HBV that do not select for resistant HIV (at approved doses) include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pegylated interferon alfa",
"     </li>",
"     <li>",
"      Standard interferon alfa",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       Adefovir",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both pegylated interferon alfa and standard interferon alfa are immunomodulatory agents with antiviral activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/15\">",
"     15",
"    </a>",
"    ]. Although interferons do not pose any risk of drug resistance to HIV or HBV, there are scant data on the use of this medication in",
"    <span class=\"nowrap\">",
"     HIV/HBV",
"    </span>",
"    coinfection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    , given as 10 mg daily, is an oral antiviral agent with modest activity against HBV infection compared with its related counterpart,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . In studies of",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients, virologic declines with adefovir were slow and the majority of patients did not achieve viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/20,26\">",
"     20,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of these various agents for the treatment of HBV in the HIV-infected patient is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37223?source=see_link\">",
"     \"Antiviral medications for the treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1960787\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES TO GUIDE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several key principles that must be considered when considering treatment of hepatitis B virus (HBV) in the HIV-infected patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3704897\">",
"    <span class=\"h2\">",
"     Does the patient require HIV therapy?",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the Department of Health and Human Services (DHHS) HIV treatment guidelines were revised to suggest HIV therapy in all patients, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/27\">",
"     27",
"    </a>",
"    ]. Supportive arguments for this significant shift in treatment recommendations include the availability of more potent agents with less toxicity and recognition that untreated HIV infection has been associated with increased morbidity and mortality related to various comorbidities, including liver disease. In addition, coformulations of various antiviral agents have vastly improved pill burden and patient adherence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patient, combination ART should utilize dually active agents, which are discussed above. (See",
"    <a class=\"local\" href=\"#H913227\">",
"     'Antiviral agents for hepatitis B virus infection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1960795\">",
"    <span class=\"h2\">",
"     Does the patient need treatment for liver disease?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment recommendations for the patient with HBV monoinfection are generally based on the presence of viremia and elevated aminotransferases and evidence of necroinflammation and fibrosis; the specific thresholds vary by treatment guideline, HBe antigen status, and liver disease staging. A detailed discussion of treatment candidacy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Who should be treated and how'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, as noted above, in the coinfected patient, treatment for HIV and HBV with a dually active agent is recommended, regardless of whether the patient has early or advanced HBV-related liver disease. The rationale to treat both infections is discussed above. (See",
"    <a class=\"local\" href=\"#H25695762\">",
"     'Patients with HIV and HBV coinfection'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3704875\">",
"    <span class=\"h2\">",
"     Issues in drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are important concerns that must be considered related to HIV and HBV drug resistance prior to initiating therapy in the treatment-naive patient or switching therapy in the treatment-experienced patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1960825\">",
"    <span class=\"h3\">",
"     HBV drug resistance in treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    monotherapy has not been associated with HBV drug resistance in either treatment-naive HBV-monoinfected patients or",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients since its approval for HBV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     Entecavir",
"    </a>",
"    is another potent agent against HBV and drug resistance in treatment-naive HBV-infected patients is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/29\">",
"     29",
"    </a>",
"    ]. However, in the HIV-infected patient, where combination therapy for HIV is also required, tenofovir is the preferred agent for dual treatment of HIV and HBV. In addition, entecavir exposure in the HIV-infected patient with detectable HIV viremia can compromise HIV therapeutic management. (See",
"    <a class=\"local\" href=\"#H1960921\">",
"     'HIV drug resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    monotherapy is associated with high rates of drug resistance among HBV-infected patients, with or without HIV infection, and is no longer considered a first-line agent for HBV treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the risk of developing HBV drug resistance to lamivudine (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ) is low when either drug is combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/31\">",
"     31",
"    </a>",
"    ]. Furthermore, the availability of the coformulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (ie, Truvada) provides patient convenience of a daily single tablet for the treatment of both HIV and HBV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , versus lamivudine or emtricitabine alone, is particularly important in the patient with cirrhosis. The emergence of drug-resistant virus in such a patient can lead to hepatic flares and liver decompensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2235579\">",
"    <span class=\"h3\">",
"     HBV drug resistance in treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is still the preferred treatment option for HBV therapy among treatment-experienced patients, since tenofovir drug resistance has not been described in patients with a history of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/28\">",
"     28",
"    </a>",
"    ]. Such patients may also benefit from continuation of lamivudine (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ) for HIV care if the patient&rsquo;s HIV isolate is still susceptible.",
"   </p>",
"   <p>",
"    In the uncommon patient with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    drug resistance, who also cannot take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is a good therapeutic option, with some important caveats. The in vitro potency of entecavir is lower against lamivudine-resistant HBV isolates compared with wild-type virus; thus, the standard dose of entecavir must be increased from 0.5 mg to 1 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/32\">",
"     32",
"    </a>",
"    ]. In fact, we generally use 1 mg of entecavir in all",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients due to concerns about possible underlying lamivudine resistance, which may not be detected on drug resistance testing. This higher dose of entecavir is similar in cost and has a similar side effect profile, thus offering overall benefit with little risk.",
"   </p>",
"   <p>",
"    In addition, the risk of developing drug resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    is approximately 1 percent during the first year of treatment increasing to 9 percent during the second year of treatment in HBV-infected patients with pre-existing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is the preferred agent in patients with lamivudine drug resistance, whenever feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/31\">",
"     31",
"    </a>",
"    ]. As noted above, tenofovir also offers dual potent activity against HIV and HBV, which serves to simplify medication regimens for patients.",
"   </p>",
"   <p>",
"    Since pegylated interferon is not a specific antiviral agent, it is not associated with HBV drug resistance; however, its efficacy for the treatment of HBV in HIV-infected patients has not been well studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37223?source=see_link&amp;anchor=H11389507#H11389507\">",
"     \"Antiviral medications for the treatment of hepatitis B in the HIV-infected patient\", section on 'Interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1960921\">",
"    <span class=\"h3\">",
"     HIV drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because some agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    have dual activity against HIV and HBV, they must be used as part of suppressive therapy for HIV; otherwise, HIV drug resistance will evolve. Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or tenofovir-lamivudine must be combined with a third antiretroviral agent for effective HIV suppression. Emtricitabine and lamivudine are never used in combination since they are structurally similar agents with significant HIV (and HBV) cross-resistance.",
"   </p>",
"   <p>",
"    Initially, it was believed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    did not have activity against HIV infection. However, subsequent clinical and in vitro data showed that use of entecavir in an HIV-infected patient with detectable HIV RNA can lead to an M184V mutation, which confers drug resistance to potent HIV agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , thus compromising HIV care [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Thus, entecavir should only be used to treat HBV in the HIV-infected patient who has attained complete HIV RNA suppression. Entecavir may have a role in the",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patient who cannot take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H913317\">",
"     'Treatment recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H913317\">",
"    <span class=\"h1\">",
"     TREATMENT RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic interventions for the HIV treatment-naive and treatment-experienced patient are discussed below. Although the treatment approach is similar, there are some fine distinctions about drug resistance, which also must be considered based on prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    exposure.",
"   </p>",
"   <p>",
"    Clinicians should be cognizant that few controlled studies for the treatment of chronic hepatitis B virus (HBV) in the HIV-infected patient have been published. Much of what is recommended here is based on known potency of antiviral agents in HBV monoinfection, results of small uncontrolled studies in",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients, or retrospective analysis of subsets of",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients in treatment trials for HIV infection.",
"   </p>",
"   <p>",
"    The rationale for the treatment of the HIV-infected patient, regardless of CD4 cell count, is discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/27\">",
"     27",
"    </a>",
"    ]. Prior to HIV treatment, an HIV drug resistance assay should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H913450\">",
"    <span class=\"h2\">",
"     Treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In treatment-naive patients infected with both HIV and HBV, we suggest the use of dually-active agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      (coformulated as Truvada&reg;) once daily as part of a fully suppressive combination antiretroviral therapy (ART) regimen for HIV infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    are considered first-line agents for the treatment of HIV infection because of potency and tolerability; together they provide the dual nucleoside analog backbone that is used in most combination regimens. An HIV protease inhibitor, nonnucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor is added as the third HIV active agent for three-drug combination ART. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV RNA suppression usually occurs within 12 weeks of initiation of ART; lack of viral suppression should lead to an evaluation for HIV drug resistance and adherence. However, HBV DNA suppression is slower; in one observational study, only 70 percent had achieved HBV DNA suppression within two years of treatment initiation with combination",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/22\">",
"     22",
"    </a>",
"    ]. Fortunately,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    resistance has not yet been documented despite ongoing HBV replication. (See",
"    <a class=\"local\" href=\"#H3704875\">",
"     'Issues in drug resistance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients with renal insufficiency is discussed below. (See",
"    <a class=\"local\" href=\"#H3705560\">",
"     'Patients with renal insufficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H913443\">",
"    <span class=\"h2\">",
"     Treatment-experienced patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of medication adherence is unlikely to explain HBV viremia in the setting of HIV viral suppression. Patients who have been taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    for more than 12 to 24 months, without coadministration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , are at high risk of HBV-related drug resistance.",
"   </p>",
"   <p>",
"    In this clinical scenario,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is often effective in achieving HBV DNA suppression, regardless of whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    is continued or not [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/22,38,39\">",
"     22,38,39",
"    </a>",
"    ]. However, due to their shared structural similarity, any patient who is lamivudine-resistant should",
"    <strong>",
"     not",
"    </strong>",
"    be considered for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    therapy due to cross-resistance, and vice versa. In a patient who is already taking two nucleoside reverse transcriptase inhibitors (NRTIs), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and lamivudine, abacavir can be switched to tenofovir for its combined HIV and HBV activity; lamivudine or emtricitabine may be maintained for HIV therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8489865\">",
"    <span class=\"h1\">",
"     MONITORING FOR ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6119?source=see_link&amp;anchor=H33402571#H33402571\">",
"      \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\", section on 'Monitoring for drug side effects'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3705560\">",
"    <span class=\"h1\">",
"     PATIENTS WITH RENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/hepatitis",
"    B virus (HBV)-coinfected patients with renal insufficiency pose additional management challenges.",
"    <span class=\"nowrap\">",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3706040\">",
"    <span class=\"h2\">",
"     Treatment-naive patients with pre-existing renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV/HBV-coinfected",
"    patients with pre-existing renal insufficiency should be evaluated for the etiology of their kidney disease, which could include HIV-associated nephropathy, HBV-associated cryoglobulinemia, diabetes, or hypertension among others. The medical work-up may include a 24-hour urine for protein and an ultrasound of the kidneys, as discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"     \"Overview of kidney disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    should be used with caution in",
"    <span class=\"nowrap\">",
"     HIV/HBV-coinfected",
"    </span>",
"    patients with pre-existing renal insufficiency since dosing adjustments that are recommended for tenofovir have been made only on the basis of pharmacokinetic studies; there are no efficacy or safety data regarding HIV treatment at reduced doses of tenofovir [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, patients should be monitored carefully for any HIV RNA breakthrough (eg, every three to four months).",
"   </p>",
"   <p>",
"    Patients who have renal insufficiency secondary to HIV nephropathy may have improvement in their renal function with initiation of renally-dosed antiretroviral therapy (ART). Those who have HBV-related renal disease may also have improvements in serum creatinine with initiation of an HBV-active regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link&amp;anchor=H11211178#H11211178\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Use in patients with renal or hepatic insufficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2008226\">",
"    <span class=\"h2\">",
"     Patients who develop renal insufficiency on tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    itself has been associated with modest increases in serum creatinine, proteinuria, proximal tubular disease, and chronic renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The risk of renal insufficiency may be somewhat higher in patients taking HIV protease inhibitors and in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/43\">",
"     43",
"    </a>",
"    ]. Serum creatinine should be assessed periodically (eg, every three months) and a urinalysis should be performed every six months to assess for proteinuria; more frequent assessment for proteinuria is prudent in patients with underlying hypertension or diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/27\">",
"     27",
"    </a>",
"    ]. Tenofovir should be discontinued among those who develop severe chronic renal insufficiency (ie, glomerular filtration rate &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, rapid changes in serum creatinine can occur related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -associated proximal tubulointerstitial nephritis. Signs of tubulopathy (eg, urinary phosphate wasting, glycosuria) may be detected despite normal serum glucose and phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16185/abstract/44\">",
"     44",
"    </a>",
"    ]. Discontinuation of tenofovir is usually associated with improvement in renal abnormalities.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is discontinued, the patient should be continued on a different ART regimen to maintain HIV suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"     \"Modifying HIV antiretroviral therapy regimens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To decrease the risk of an HBV-related flare,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    should be added to a fully suppressive three-drug HIV combination regimen. If the patient has documented or suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    drug resistance, there is also the risk of developing HBV drug resistance with entecavir exposure. Patients should have serial monitoring of aminotransferases and HBV DNA every three months during entecavir-based HBV therapy; a significant flare in aminotransferases would suggest virologic breakthrough. Patients should be instructed to see their doctor if they note the onset of right upper quadrant pain, nausea, vomiting, fatigue, jaundice, or loss of appetite. The dosing of entecavir will depend on degree of renal insufficiency (eg, 0.5 mg daily for creatinine clearance of 30 to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and 0.3 mg daily for creatinine clearance of 10 to 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and 0.1",
"    <span class=\"nowrap\">",
"     mg/daily",
"    </span>",
"    for patients on hemodialysis). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1961454\">",
"    <span class=\"h1\">",
"     MONITORING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and laboratory monitoring during therapy are important to determine the efficacy of therapy. Monitoring of the HIV patient coinfected with hepatitis B virus is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6119?source=see_link\">",
"     \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment and prevention of hepatitis B virus (HBV) infection has taken on great significance in light of the negative impact HIV has on the natural history of chronic liver disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many rationales to treat both HIV and HBV in the coinfected patient.",
"      <span class=\"nowrap\">",
"       HIV/HBV-coinfected",
"      </span>",
"      patients have faster rates of fibrosis progression and an increased risk of cirrhosis, end-stage liver disease (ESLD), and hepatocellular carcinoma (HCC) than patients with HBV infection alone. Furthermore, immunosuppression, secondary to uncontrolled HIV infection, is associated with an increased risk of liver-related mortality. Finally, treatment of both infections appears to be safer than just HIV alone; when antiretroviral medications that do not have any activity against HBV are selected for treatment of HIV, immunologic recovery secondary to HIV treatment can lead to significant liver injury. (See",
"      <a class=\"local\" href=\"#H7931840\">",
"       'Rationale to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the optimal goal of treatment is long-lasting control of HBV infection, as indicated by hepatitis B surface antigen seroconversion, the vast majority of patients do not reach this endpoint. Other primary treatment goals include viral suppression, improving liver histology, and preventing progression of end-stage liver disease and the onset of hepatocellular carcinoma. (See",
"      <a class=\"local\" href=\"#H912788\">",
"       'Goals of hepatitis B virus therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because some agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      have dual activity against HIV and HBV, they must be used as part of suppressive three-drug combination therapy for HIV; otherwise, HIV drug resistance will evolve. (See",
"      <a class=\"local\" href=\"#H1960921\">",
"       'HIV drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      has not been associated with any report of HBV drug resistance to date, including among patients with prior",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      drug resistance. Treatment of HBV infection in HIV-infected patients with lamivudine alone is associated with high rates of HBV drug resistance after one year of therapy. However, the risk of lamivudine (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      ) drug resistance is much lower when tenofovir is coadministered. (See",
"      <a class=\"local\" href=\"#H1960825\">",
"       'HBV drug resistance in treatment-naive patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      HBV drug resistance is low in treatment-naive patients; however, the risk increases among those with suspected",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      drug resistance who have ongoing HBV viremia during entecavir drug exposure. Entecavir also has modest activity against HIV and can induce drug resistance to lamivudine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      if used in a patient with ongoing HIV viremia. Thus, entecavir should only be used in conjunction with a fully suppressive antiretroviral therapy (ART) regimen for HIV. (See",
"      <a class=\"local\" href=\"#H913227\">",
"       'Antiviral agents for hepatitis B virus infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ART is recommended in all HIV-infected patients, regardless of CD4 cell counts, by various guideline panels; the strength of the evidence varies by the CD4 cell count. Supportive arguments for this significant shift in treatment recommendations include the availability of more potent agents with less toxicity and recognition that untreated HIV infection has been associated with increased morbidity and mortality related to various comorbidities, including liver disease. The evidence and grading of the recommendations based on CD4 cell count are found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When initiating ART in the HIV-infected patient with HBV coinfection, we recommend using antiviral agents with dual activity against HIV and HBV, regardless of whether the patient has established liver disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In HIV treatment-naive patients with HBV coinfection, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (one tablet orally daily) as part of a fully suppressive three-drug combination ART regimen for HIV infection. (See",
"      <a class=\"local\" href=\"#H913450\">",
"       'Treatment-naive patients'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In HIV treatment-experienced patients who have detectable HBV DNA on a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      -containing ART regimen, we prefer to add",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      (300 mg orally daily) to achieve HBV DNA suppression. Among patients who are taking dual nucleoside reverse transcriptase inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      and lamivudine, tenofovir can be substituted for abacavir to treat the patient&rsquo;s underlying HIV and HBV infection while lamivudine can be maintained for its HIV activity. (See",
"      <a class=\"local\" href=\"#H913443\">",
"       'Treatment-experienced patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV/HBV-coinfected",
"      </span>",
"      patients with pre-existing renal insufficiency should be evaluated for the etiology of their kidney disease, which could include HIV-associated nephropathy, HBV-associated cryoglobulinemia, diabetes, or hypertension among others. The medical work-up may include a 24 hour urinalysis and renal ultrasound, as discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"       \"Overview of kidney disease in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have renal insufficiency secondary to HIV nephropathy may have improvement in their renal function with initiation of renally-dosed antiretroviral therapy. Those who have HBV-related renal disease may also have improvements in serum creatinine with initiation of an HBV-active regimen. (See",
"      <a class=\"local\" href=\"#H3706040\">",
"       'Treatment-naive patients with pre-existing renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       HIV/HBV",
"      </span>",
"      coinfected patients who are being treated with a renally-reduced dosage of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      should be monitored carefully for any HIV RNA breakthrough (eg, every three to four months). (See",
"      <a class=\"local\" href=\"#H3706040\">",
"       'Treatment-naive patients with pre-existing renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, rapid increases in serum creatinine can occur related to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -associated proximal tubulointerstitial nephritis. Discontinuation of tenofovir is usually associated with improvement in renal abnormalities. If tenofovir is discontinued, the patient should be switched to a different ART regimen to maintain HIV suppression. To decrease the risk of an HBV-related flare, renally-dosed",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      should be added to a fully suppressive three-drug HIV combination regimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=see_link\">",
"       \"Modifying HIV antiretroviral therapy regimens\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2008226\">",
"       'Patients who develop renal insufficiency on tenofovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical and laboratory monitoring during therapy are important to determine the efficacy of antiviral therapy. Monitoring of the",
"      <span class=\"nowrap\">",
"       HIV/HBV-coinfected",
"      </span>",
"      patient is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6119?source=see_link\">",
"       \"Monitoring the HIV-infected patient with chronic hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/1\">",
"      Weber R, Sabin CA, Friis-M&oslash;ller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/2\">",
"      Falade-Nwulia O, Seaberg EC, Rinaldo CR, et al. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis 2012; 55:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/3\">",
"      Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/4\">",
"      Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/5\">",
"      Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/6\">",
"      Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/7\">",
"      Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/8\">",
"      Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/9\">",
"      Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/10\">",
"      Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/11\">",
"      Br&auml;u N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/12\">",
"      Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49:S138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/13\">",
"      Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/14\">",
"      Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226.",
"     </a>",
"    </li>",
"    <li>",
"     file://aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf (Accessed on February 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/16\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/17\">",
"      Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/18\">",
"      Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/19\">",
"      Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/20\">",
"      Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/21\">",
"      Puoti M, Cozzi-Lepri A, Paraninfo G, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006; 11:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/22\">",
"      de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139:1934.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on January 20, 2011).",
"    </li>",
"    <li>",
"     Low E, Cox A, Atkins M, Nelson M. Telbivudine Has Activity against HIV. 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009). Montreal, Canada. February 8-11, 2009. Abstract 813a.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/25\">",
"      Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/26\">",
"      Sheldon JA, Corral A, Rod&eacute;s B, et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS 2005; 19:2036.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/ (Accessed on May 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/28\">",
"      Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/29\">",
"      Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside na&iuml;ve patients with hepatitis B. Hepatology 2006; 44:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/30\">",
"      Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/31\">",
"      Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/32\">",
"      Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81:3992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/33\">",
"      Walsh AW, Langley DR, Colonno RJ, Tenney DJ. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One 2010; 5:e9195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/34\">",
"      Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/35\">",
"      McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/36\">",
"      Sasadeusz J, Audsley J, Mijch A, et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008; 22:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/37\">",
"      Domaoal RA, McMahon M, Thio CL, et al. Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. J Biol Chem 2008; 283:5452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/38\">",
"      Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/39\">",
"      Avihingsanon A, Lewin SR, Kerr S, et al. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. Antivir Ther 2010; 15:917.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi_041009.pdf (Accessed on June 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/41\">",
"      Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/42\">",
"      Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/43\">",
"      Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009; 23:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16185/abstract/44\">",
"      Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 2010; 78:1171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3652 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16185=[""].join("\n");
var outline_f15_51_16185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7931840\">",
"      RATIONALE TO TREAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25695747\">",
"      Patients with HBV alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25695762\">",
"      Patients with HIV and HBV coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H912788\">",
"      GOALS OF HEPATITIS B VIRUS THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H913227\">",
"      ANTIVIRAL AGENTS FOR HEPATITIS B VIRUS INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1960787\">",
"      GENERAL PRINCIPLES TO GUIDE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3704897\">",
"      Does the patient require HIV therapy?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1960795\">",
"      Does the patient need treatment for liver disease?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3704875\">",
"      Issues in drug resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1960825\">",
"      - HBV drug resistance in treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2235579\">",
"      - HBV drug resistance in treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1960921\">",
"      - HIV drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H913317\">",
"      TREATMENT RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H913450\">",
"      Treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H913443\">",
"      Treatment-experienced patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8489865\">",
"      MONITORING FOR ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3705560\">",
"      PATIENTS WITH RENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3706040\">",
"      Treatment-naive patients with pre-existing renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2008226\">",
"      Patients who develop renal insufficiency on tenofovir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1961454\">",
"      MONITORING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37223?source=related_link\">",
"      Antiviral medications for the treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44020?source=related_link\">",
"      Evaluation of chronic hepatitis B virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36265?source=related_link\">",
"      Modifying HIV antiretroviral therapy regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6119?source=related_link\">",
"      Monitoring the HIV-infected patient with chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16186="Overview of thyroid disease in pregnancy";
var content_f15_51_16186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of thyroid disease in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16186/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16186/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16186/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16186/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16186/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/51/16186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/51/16186/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/51/16186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation and treatment of pregnant women with thyroid disease parallel that of nonpregnant women and men, but present some unique problems. An overview of thyroid physiology and disease during pregnancy is presented here. Some of the disorders reviewed below are discussed separately in individual topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THYROID ADAPTATION DURING NORMAL PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of thyroid disease during pregnancy requires an understanding of the changes in thyroid physiology and thyroid function tests that accompany normal pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1156377\">",
"    <span class=\"h2\">",
"     Thyroid physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;To meet the increased metabolic needs during a normal pregnancy, there are changes in thyroid physiology that are reflected in altered thyroid function tests [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/1\">",
"     1",
"    </a>",
"    ]. The major changes in thyroid function during pregnancy are an increase in serum thyroxine-binding globulin (TBG) concentrations and stimulation of the thyrotropin (TSH) receptor by human chorionic gonadotropin (hCG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H994015\">",
"    <span class=\"h3\">",
"     Thyroxine binding globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, serum TBG concentrations rise almost two-fold because estrogen increases TBG production and TBG sialylation, which results in decreased clearance of TBG [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/2\">",
"     2",
"    </a>",
"    ]. To maintain adequate free thyroid hormone concentrations during this period, thyroxine (T4) and triiodothyronine (T3) production by the thyroid gland must increase. Total T4 and T3 concentrations rise during the first half of pregnancy, plateauing at approximately 20 weeks of gestation, at which time a new steady state is reached and the overall production rate of thyroid hormones returns to prepregnancy rates. Thus, TBG excess leads to an increase in both serum total thyroxine (T4) and triiodothyronine (T3) concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H994022\">",
"    <span class=\"h3\">",
"     hCG and thyroid function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human chorionic gonadotropin (hCG) is one of a family of glycoprotein hormones, including thyrotropin (TSH), with a common alpha-subunit and a unique beta-subunit. However, there is considerable homology between the beta-subunits of hCG and TSH. As a result, hCG has weak thyroid-stimulating activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/3\">",
"     3",
"    </a>",
"    ]. In a human thyroid cell-culture assay, as an example, 1 microU of hCG was equivalent to 0.0013 microU of TSH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum hCG concentrations increase soon after fertilization and peak at 10 to 12 weeks. During this peak, total serum T4 and T3 concentrations increase. Serum free T4 and T3 concentrations increase slightly, usually within the normal range, and serum TSH concentrations are appropriately reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/3\">",
"     3",
"    </a>",
"    ]. However, in 10 to 20 percent of normal women, serum TSH concentrations are transiently low or undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In a report of 63 women with extremely high hCG concentrations (&gt;200,000",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    TSH was &lt;0.2",
"    <span class=\"nowrap\">",
"     microU/mL",
"    </span>",
"    in 67 percent of samples and free T4 was above 1.8",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    in 32 percent of samples. All women whose hCG was greater than 400,000",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    had a suppressed TSH concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H12187099#H12187099\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'hCG-mediated hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This transient, usually subclinical, hyperthyroidism should be considered a normal physiologic finding. It is not known if this action of hCG benefits the mother or fetus. Later in pregnancy, as hCG secretion declines, serum free T4 and T3 concentrations decline and serum TSH concentrations rise slightly to or within the normal range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1156384\">",
"    <span class=\"h2\">",
"     Trimester-specific reference ranges",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the changes in thyroid physiology during pregnancy, the Guidelines of the American Thyroid Association (ATA) for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum recommend using trimester-specific reference ranges for TSH and method and trimester-specific reference ranges for serum free T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ]. Commercial laboratories should provide these reference ranges, but many commercial laboratories currently do not do this.",
"   </p>",
"   <p>",
"    In several population studies, the lower limit of the reference range for TSH in healthy pregnant women during the first trimester ranged from 0.03 to 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. In one of the largest population-based studies (over 13,000 pregnant women), the reference range (2.5 to 97.5",
"    <sup>",
"     th",
"    </sup>",
"    &nbsp;percentile) for TSH in the first trimester was 0.08 to 2.99",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Thus, if the laboratory does not provide trimester-specific reference ranges for TSH",
"    <span class=\"nowrap\">",
"     (mU/L),",
"    </span>",
"    the following reference ranges can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First trimester 0.1 to 2.5",
"     </li>",
"     <li>",
"      Second trimester 0.2 to 3.0",
"     </li>",
"     <li>",
"      Third trimester 0.3 to 3.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some studies report a decrease in free T4 during pregnancy, others report no change or even an increase [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ]. Direct free T4 measurements may be unreliable during pregnancy. Measurement of free T4 in the dialysate or ultrafiltrate of serum samples using liquid",
"    <span class=\"nowrap\">",
"     chromatography/tandem",
"    </span>",
"    mass spectrometry appears to be the most reliable, and when this method is used, free T4 concentrations were shown to decrease gradually with advancing gestational age, particularly between the first and second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This assay is relatively expensive and not universally available. Other free T4 assays (and probably free T3 assays) frequently fail to meet performance standards in pregnant patients, owing to increases in TBG and decreases in albumin concentrations that cause the immunoassay to be unreliable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/15\">",
"     15",
"    </a>",
"    ]. To compensate, some kits have provided different free T4 normal ranges for pregnant patients, usually lower than those of nonpregnant patients. Method-specific and trimester-specific reference ranges of serum free T4 should be used, if available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=see_link&amp;anchor=H5#H5\">",
"     \"Laboratory assessment of thyroid function\", section on 'Serum free T4 and free T3'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an alternative, serum total T4 measurements, which are more reliable during pregnancy, can be measured to assess thyroid function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/15\">",
"     15",
"    </a>",
"    ]. When free T4 measurements appear discordant with TSH measurements, serum total T4 should be measured. Total T4 and T3 levels during pregnancy are 1.5-fold higher than in nonpregnant women due to TBG excess. Thus a normal reference range for pregnancy should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1156391\">",
"    <span class=\"h2\">",
"     Iodine requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine requirements are higher in pregnant than in nonpregnant women due to the increase in maternal T4 production required to maintain maternal euthyroidism and increased renal iodine clearance. Severe maternal iodine deficiency during pregnancy results in a reduction in maternal thyroxine production, inadequate placental transfer of maternal thyroxine, and impairment of fetal neurologic development. However, markedly excessive iodine intake may also be harmful as it can lead to fetal hypothyroidism and goiter.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) recommends 250 mcg of iodine daily during pregnancy and lactation. The Institute of Medicine recommends daily iodine intake of 220 mcg during pregnancy and 290 mcg during lactation. For women in the US to achieve this level of daily intake, the ATA recommends that women from the US receive a supplement of 150 mcg of iodine daily during pregnancy and lactation, which is the dose included in the majority of prenatal vitamins marketed in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    .) The tolerable upper intake amount for iodine, as established by European and US expert committees, ranges from 600 to 1100 mcg daily for adults and pregnant women &gt;19 years of age.",
"   </p>",
"   <p>",
"    Iodine requirements and the consequences of inadequate and excess intake are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link&amp;anchor=H147486325#H147486325\">",
"     \"Iodine deficiency disorders\", section on 'Iodine requirements'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link&amp;anchor=H59356473#H59356473\">",
"     \"Iodine deficiency disorders\", section on 'Pregnancy and lactation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link&amp;anchor=H59356843#H59356843\">",
"     \"Iodine deficiency disorders\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=see_link&amp;anchor=H5#H5\">",
"     \"Iodine-induced thyroid dysfunction\", section on 'Iodine-induced thyroid disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     THYROID FUNCTION IN THE FETUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    week of gestation, fetal TSH appears and the fetal thyroid is capable of concentrating iodine and synthesizing iodothyronines. However, little hormone synthesis occurs until the 18",
"    <sup>",
"     th",
"    </sup>",
"    to 20",
"    <sup>",
"     th",
"    </sup>",
"    week. Thereafter, fetal thyroid secretion increases gradually [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At term, fetal serum T4, T3, and TSH concentrations differ substantially from those in the mothers. Serum TSH concentrations are higher, serum free T4 concentrations are lower, and serum T3 concentrations are one-half those of the mothers. Soon after birth, serum TSH concentrations rapidly increase to 50 to 80",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    and then fall to 10 to 15",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    within 48 hours. Serum T3 and T4 concentrations rapidly increase to values slightly higher than those in normal adults.",
"   </p>",
"   <p>",
"    The extent to which maternal thyroid hormones cross the placenta is controversial. In infants with congenital absence of the thyroid, cord serum concentrations range from 20 to 50 percent of the concentrations in normal infants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/21\">",
"     21",
"    </a>",
"    ]. TSH-receptor antibodies can cross the placenta and cause either fetal hyperthyroidism or hypothyroidism. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Fetal and neonatal Graves' disease'",
"    </a>",
"    below.) Little TSH crosses the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/22\">",
"     22",
"    </a>",
"    ]. Thyrotropin-releasing hormone (TRH) can cross the placenta and exogenously administered TRH can stimulate fetal TSH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HYPERTHYROIDISM COMPLICATING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overt hyperthyroidism (suppressed TSH, elevated free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T3) is relatively uncommon during pregnancy, occurring in 0.1 to 0.4 percent of all pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/24\">",
"     24",
"    </a>",
"    ]. Although hyperthyroidism from any cause can complicate pregnancy, Graves' and hCG-mediated hyperthyroidism are the most common causes of hyperthyroidism. Graves&rsquo; disease usually becomes less severe during the later stages of pregnancy due to a reduction in TSH receptor antibody concentrations or, rarely, mediated by a change in the activity of TSH receptor antibodies from stimulatory to blocking. hCG-mediated hyperthyroidism may occur transiently in the first half of gestation and is typically less severe than Graves&rsquo; disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H12186870#H12186870\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Establishing the cause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16385488\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy complicated by poorly controlled overt hyperthyroidism (most often due to Graves&rsquo; disease) is associated with increased rates of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous abortion",
"     </li>",
"     <li>",
"      Premature labor",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"     <li>",
"      Stillbirth",
"     </li>",
"     <li>",
"      Preeclampsia",
"     </li>",
"     <li>",
"      Heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Very rare cases of thyroid storm precipitated by labor, infection, preeclampsia, or cesarean section have been reported.",
"   </p>",
"   <p>",
"    In contrast to these findings, subclinical hyperthyroidism (low TSH with normal free T4) has not been associated with adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hyperthyroidism during pregnancy should be based primarily upon a finding of a suppressed (&lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    or undetectable (&lt;0.01) serum TSH value and elevated thyroid hormone levels that exceed the normal range for pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ]. If a TSH level is &lt;0.1",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    free T4 (or free T4 index) should be obtained. If the free T4 is in the normal range for pregnancy, a free T3 should also be measured. In the event that free thyroid hormone levels are discordant with serum TSH and clinical findings, total T4 should be measured.",
"   </p>",
"   <p>",
"    TSH in healthy pregnant women during the first trimester may be as low as 0.03 to 0.1",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Most pregnant women with significant overt hyperthyroidism in the first trimester will have a serum TSH below that which is seen in asymptomatic healthy pregnant women (ie, &lt;0.01",
"    <span class=\"nowrap\">",
"     mU/L)",
"    </span>",
"    associated with an elevated free T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    free T3 (or total T4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    total T3) measurement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H994499#H994499\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because radioiodine administration is contraindicated, it may not be possible to ascertain the cause of the hyperthyroidism during pregnancy. Measurement of thyrotropin receptor antibody (TRAb or thyroid stimulating immunoglobulins) using second-generation thyrotropin-binding inhibitory immunoglobulin (TBII) assays are positive in 95 percent of patients with Graves' disease and should be used to make the diagnosis of Graves' disease during pregnancy if the clinical diagnosis is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H994499#H994499\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;hCG-mediated hyperthyroidism is usually transient and does not require treatment. Treatment options for pregnant women with overt hyperthyroidism due to Graves&rsquo; or nodular thyroid disease are limited because therapy may be harmful to the fetus. However, a good fetal and maternal outcome depends upon controlling the mother's hyperthyroidism. The goal of treatment is to reduce and maintain the mother's serum free T4 concentration in the high normal range for nonpregnant women using the lowest drug dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ]. This requires assessment of free T4",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    total T4) frequently (ie, at four-week intervals) with appropriate adjustment of medication. Treatment recommendations are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fetal and neonatal Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;One to 5 percent of neonates born to women with Graves' disease have hyperthyroidism due to transplacental transfer of TSH receptor-stimulating antibodies. The incidence is higher in women with high titers of these antibodies.",
"   </p>",
"   <p>",
"    High fetal heart rate (&gt;160",
"    <span class=\"nowrap\">",
"     beats/minute),",
"    </span>",
"    fetal goiter, advanced bone age, poor growth, and craniosynostosis are manifestations of fetal hyperthyroidism. Cardiac failure and hydrops may occur with severe disease. All fetuses of women with Graves' disease should be monitored for signs of fetal thyrotoxicosis by determination of fetal heart rate and assessment of fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link\">",
"     \"Evaluation and management of neonatal Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link&amp;anchor=H13#H13\">",
"     \"Hyperthyroidism during pregnancy: Treatment\", section on 'Fetal hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HYPOTHYROIDISM DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When iodine nutrition is adequate (as in the US), the most common cause of hypothyroidism during pregnancy is chronic autoimmune (Hashimoto&rsquo;s) thyroiditis. In iodine deficient areas, iodine deficiency itself is associated with hypothyroidism and goiter. Other causes of hypothyroidism, such as prior radioiodine ablation of the thyroid or disorders of the pituitary or hypothalamus, can also occur in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57694701\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothyroidism can have adverse effects on the mother and child, depending upon the severity of the biochemical abnormalities. This topic is reviewed briefly below and in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693617#H57693617\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overt hypothyroidism (elevated TSH, reduced free T4) complicating pregnancy is unusual (0.3 to 0.5 percent of screened women), owing to a reduced fertility rate in hypothyroid women and a high rate of first trimester spontaneous abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In continuing pregnancies, overt hypothyroidism has been associated with an increased risk of several complications, including [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/32-38\">",
"     32-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preeclampsia and gestational hypertension",
"     </li>",
"     <li>",
"      Placental abruption",
"     </li>",
"     <li>",
"      Nonreassuring fetal heart rate tracing",
"     </li>",
"     <li>",
"      Preterm delivery, including very preterm delivery (before 32 weeks)",
"     </li>",
"     <li>",
"      Low birth weight (which was likely due to preterm delivery for preeclampsia in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/36\">",
"       36",
"      </a>",
"      ], but not in a second study where the rate of preeclampsia was negligible) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased rate of cesarean section [",
"      <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Perinatal morbidity and mortality",
"     </li>",
"     <li>",
"      Neuropsychological and cognitive impairment",
"     </li>",
"     <li>",
"      Postpartum hemorrhage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subclinical hypothyroidism (elevated TSH, normal free T4) is far more common than overt hypothyroidism, occurring in 2 to 2.5 percent of screened women in the US (iodine sufficient region) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The risk of pregnancy complications is lower in women with subclinical rather than overt hypothyroidism. However, in some studies, women with subclinical hypothyroidism were also at increased risk for preterm delivery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pregnancy loss. It is uncertain if the children of women with subclinical hypothyroidism are at risk for neuropsychological impairment.",
"   </p>",
"   <p>",
"    Isolated hypothyroxinemia (low T4) is defined as a maternal free T4 concentration in the lower 5",
"    <sup>",
"     th",
"    </sup>",
"    or 10",
"    <sup>",
"     th",
"    </sup>",
"    percentile of the reference range, in conjunction with a normal TSH. The effect of isolated maternal hypothyroxinemia on perinatal and neonatal outcome is also unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1156783\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of primary hypothyroidism during pregnancy is based upon the finding of an elevated serum TSH concentration, defined using trimester-specific TSH reference ranges for pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ]. For women in the first trimester of pregnancy with a TSH above 2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    (above 3",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    in the second and third trimester), we also measure a free T4. Overt hypothyroidism is defined as an elevated trimester-specific TSH concentration in conjunction with a decreased free T4 concentration (below assay normal using reference range for pregnant women). Subclinical hypothyroidism is defined as an elevated trimester-specific serum TSH concentration and a normal free T4 concentration.",
"   </p>",
"   <p>",
"    Women with central hypothyroidism from pituitary or hypothalamic disease will not have elevated TSH concentrations during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link&amp;anchor=H22447146#H22447146\">",
"     \"Central hypothyroidism\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The universal screening of asymptomatic pregnant women for hypothyroidism during the first trimester of pregnancy is controversial. This topic is reviewed briefly below and in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693652#H57693652\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of insufficient evidence to support universal TSH screening in the first trimester, most professional societies, including the ATA, the Endocrine Society, and the American College of Obstetricians and Gynecologists (ACOG) recommend targeted case finding rather than universal screening [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9,42-44\">",
"     9,42-44",
"    </a>",
"    ]. The ATA recommends measurement of serum TSH in pregnant women if they are symptomatic, from an area of known moderate to severe iodine insufficiency, or have a family or personal history of thyroid disease, thyroid peroxidase antibodies (TPOAb), type 1 diabetes, history of preterm delivery or miscarriage, history of head or neck radiation, morbid obesity (BMI &ge;40",
"    <span class=\"nowrap\">",
"     kg/m2),",
"    </span>",
"    infertility, or age &gt;30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this approach may miss up to one-third of women with hypothyroidism and preliminary data suggest that universal screening is cost-effective if one assumes that treatment improves the offspring IQ. Therefore, some endocrinologists have argued for universal screening for thyroid dysfunction in pregnant women or those planning to become pregnant in the near future [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest a targeted approach to screening. We favor screening pregnant women if they are from an area of moderate to severe iodine insufficiency, have symptoms of hypothyroidism, a family or personal history of thyroid disease, or a personal history of thyroid peroxidase antibodies, type 1 diabetes, head and neck radiation, recurrent miscarriage, morbid obesity, or infertility. In women who meet the screening criteria, we measure serum TSH during the first trimester. If the serum TSH is normal, no further testing is performed. If the TSH is &gt;2.5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    free T4 should be measured to determine the degree of hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1156716\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A good fetal and maternal outcome depends upon treating maternal hypothyroidism with thyroid hormone (thyroxine, T4). The goal of treatment is to maintain the mother's serum TSH in the trimester-specific reference range (0.1 to 2.5",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    0.2 to 3",
"    <span class=\"nowrap\">",
"     mU/L,",
"    </span>",
"    and 0.3 to 3",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    for the first, second, and third trimesters, respectively). Women with preexisting hypothyroidism who become pregnant need more T4 during pregnancy. Dose requirements may increase by as much as 50 percent during pregnancy, and the increase occurs as early as the fifth week of gestation. The treatment of newly diagnosed and preexisting hypothyroidism is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693659#H57693659\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Congenital hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of congenital hypothyroidism are due to agenesis or dysgenesis of the fetal thyroid, congenital dyshormonogenesis, or iodine deficiency in endemic areas. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment and prognosis of congenital hypothyroidism\", section on 'Maternal hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     THYROID PEROXIDASE ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased risk of fetal loss, perinatal mortality, and large-for-gestational-age infants has been reported in euthyroid women with high serum antithyroid peroxidase antibody (TPO antibodies) concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. In meta-analyses of case-control and cohort studies, the presence of thyroid autoantibodies in euthyroid women is associated with an increased risk of spontaneous miscarriage that is two to three times higher than in women without antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In addition, the risk of preterm birth is approximately doubled [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some women, treatment with T4 may improve miscarriage rates. As an example, in a prospective study of 115 TPO antibody positive patients, half were randomly assigned to T4 (median dose 50 mcg daily) and half were not treated, and comparison was made with 869 TPO antibody negative patients. Miscarriage rates were 3.5 percent in TPO antibody positive treated patients, 2.4 percent in the TPO antibody negative patients, and 13.8 percent in TPO antibody positive untreated patients. Premature delivery rates were 7 percent, 8.2 percent, and 22.4 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37976?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of couples with recurrent pregnancy loss\", section on 'Thyroid dysfunction and diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the same study, some euthyroid women with TPO antibodies developed subclinical hypothyroidism. In early pregnancy, the TPO positive women had significantly higher serum TSH levels than TPO negative women, although the level was in the normal range. Approximately 20 percent of TPO positive women subsequently developed subclinical hypothyroidism by term if left untreated.",
"   </p>",
"   <p>",
"    Euthyroid women with positive TPO antibodies undergoing in vitro fertilization (IVF) also have higher miscarriage rates. In a meta-analysis of four observational studies (1098 women undergoing IVF), the risk of miscarriage was two-fold higher in euthyroid women with than without positive TPO antibodies (RR 1.99, 95% CI 1.42-2.78) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/52\">",
"     52",
"    </a>",
"    ]. In a randomized trial of T4 versus placebo in 72 euthyroid subfertile women with positive TPO antibodies undergoing assisted reproductive technologies (ART), however, thyroid hormone therapy did not lower the risk of early pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/53\">",
"     53",
"    </a>",
"    ]. However, these results are confounded by the presence of additional infertility factors in women undergoing ART.",
"   </p>",
"   <p>",
"    It is unclear if the presence of TPO antibodies in euthyroid pregnant women affects the cognitive or behavioral development of their children. In a population-based cohort study from the Netherlands, 4770 pregnant women had blood collected at 13.5 weeks of gestation and cord blood was obtained immediately after birth in 2121 of the neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/54\">",
"     54",
"    </a>",
"    ]. All samples were analyzed immediately post delivery for TSH, free T4, and thyroid peroxidase antibodies. TPO antibodies were elevated in 4.7 percent. TSH levels were higher in TPO positive than negative women (3.8 versus 1.5",
"    <span class=\"nowrap\">",
"     mU/L),",
"    </span>",
"    but TSH levels in the cord blood did not differ between positive and negative women. Elevated titers of TPO antibodies during pregnancy did not predict the verbal and nonverbal cognitive function of the children when tested at 2.5 years. However, children of euthyroid mothers with positive TPO antibodies were at higher risk of attention",
"    <span class=\"nowrap\">",
"     deficit/hyperactivity",
"    </span>",
"    problems (OR 1.77, 95% CI 1.15-2.72). When the analysis was adjusted for maternal TSH level, the association was attenuated but remained significant (OR 1.56).",
"   </p>",
"   <p>",
"    The decision to treat euthyroid women with elevated TPO antibodies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    (T4) or to monitor for the development of hypothyroidism during pregnancy is controversial. Most pregnant women are unlikely to know their antithyroid antibody status because universal screening is not routinely done. The ATA found there was insufficient evidence to recommend for or against thyroxine therapy in euthyroid antibody positive pregnant women; however, monitoring for the development of hypothyroidism was recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since carefully monitored thyroid hormone treatment is safe, some experts, including some UpToDate editors and the author of this topic review, suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"     levothyroxine",
"    </a>",
"    treatment (T4, 50 mcg daily) in TPO positive euthyroid women who have had recurrent miscarriage, until additional data become available. However, other experts, including other UpToDate editors, do not routinely treat euthyroid TPO positive women with T4 because of insufficient evidence of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=see_link\">",
"     \"Evaluation of couples with recurrent pregnancy loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In antibody positive euthyroid pregnant women who are not treated with thyroid hormone, TSH should be measured every four weeks during the first half of pregnancy and at least once during the last trimester to monitor for the development of hypothyroidism. Thyroid hormone should be initiated if TSH rises above the trimester-specific reference range (2.5",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    for first, and 3.0",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    for second and third trimesters).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     GOITER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased urinary iodine excretion during pregnancy may deplete thyroidal iodine stores by as much as 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/55\">",
"     55",
"    </a>",
"    ]. Plasma iodide concentrations may decrease during pregnancy due to increased maternal renal clearance and fetal uptake of iodide [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/20\">",
"     20",
"    </a>",
"    ]. Goiter during pregnancy is common in regions where iodine intake is low, occurring in 16 to 70 percent of women in iodine-deficient regions of Western Europe. Studies from Europe show that iodine depletion relative to the nonpregnant states leads to mild thyroid enlargement detectable sonographically (mean increase in volume: 18 percent), a change that is clinically detectable in some women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/1,56\">",
"     1,56",
"    </a>",
"    ]. In areas of moderate iodine deficiency, thyroid volume in women correlates with the number of previous pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1156391\">",
"     'Iodine requirements'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Goiter during pregnancy is rare in the United States (an iodine sufficient region). In the United States, any thyroid growth during pregnancy should be considered potentially abnormal, requiring further investigation with thyroid function testing and possibly thyroid sonography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590601\">",
"    <span class=\"h1\">",
"     THYROID NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas of mild to moderate iodine deficiency, the prevalence of thyroid nodules during pregnancy varies between 3 and 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. In retrospective studies, the frequency of thyroid cancer in pregnant women with thyroid nodules ranges from 12 to 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. In one prospective study, there were no malignancies among the 15 percent of women with newly detected thyroid nodules (detected via ultrasonography) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/59\">",
"     59",
"    </a>",
"    ]. The wide range of thyroid cancer prevalence is likely due to differences in patient population and study design.",
"   </p>",
"   <p>",
"    A pregnant woman found to have a thyroid nodule should be evaluated in the same way as if she were not pregnant. Thyroid function tests (TSH and free T4) and ultrasound should be performed. Thyroid radionuclide scanning is contraindicated during pregnancy. The indications for fine needle aspiration biopsy of the nodule are the same as in nonpregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9,44,62\">",
"     9,44,62",
"    </a>",
"    ]. FNA is safe to perform during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent management varies according to the biopsy results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H24#H24\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=see_link\">",
"     \"Atlas of thyroid cytopathology\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p>",
"    Rarely, benign nodules require surgery during the second trimester due to rapid growth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of compressive symptoms. When fine needle aspiration cytology shows follicular neoplasm or follicular lesion of undetermined significance, patients are frequently followed and further evaluation (thyroid scan, surgery) is delayed until after delivery, as 80 to 95 percent of these nodules are benign. Rarely, second trimester surgery is indicated due to rapid growth or the emergence of lymphadenopathy associated with a suspicious indeterminate nodule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THYROID CANCER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57692121\">",
"    <span class=\"h2\">",
"     Diagnosed during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most observational studies, thyroid cancer discovered during pregnancy does not significantly impact the prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. As an example, a California cancer registry identified 129 antepartum and 466 postpartum thyroid cancers and found no difference in overall prognosis compared to women with thyroid cancer not associated with pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with differentiated thyroid cancer require surgery. However, given the typically indolent nature of thyroid cancer, thyroidectomy is usually delayed until the postpartum period to minimize maternal and fetal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/66,71\">",
"     66,71",
"    </a>",
"    ]. This approach does not appear to have a negative impact on prognosis, as illustrated by the results of a retrospective study of 61 pregnant women with thyroid cancer of whom 77 percent delayed surgery until after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/66\">",
"     66",
"    </a>",
"    ]. There was no difference in the outcome after 20 years (recurrence or distant metastases) as compared with those women having surgery in the second trimester or nonpregnant women.",
"   </p>",
"   <p>",
"    When surgery for thyroid cancer is deferred, the patient should be monitored during pregnancy with thyroid ultrasound performed during each trimester. If by 24 weeks there is a significant increase in thyroid cancer size (50 percent in volume and 20 percent in diameter in two dimensions), surgery should be performed during the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9,72\">",
"     9,72",
"    </a>",
"    ]. However, if the size remains stable or if it is diagnosed in the second half of pregnancy, surgery may be performed after delivery. In such cases where thyroid surgery is deferred, we suggest thyroid hormone suppressive therapy with a goal of maintaining the TSH in the range of 0.1 to 1.5",
"    <span class=\"nowrap\">",
"     mU/L.",
"    </span>",
"   </p>",
"   <p>",
"    Surgery during pregnancy is sometimes indicated for rare patients with larger, more aggressive or rapidly growing cancers, or in the presence of extensive nodal or distant metastasis. The safest time for any type of surgery during pregnancy is the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9,62,73\">",
"     9,62,73",
"    </a>",
"    ]. However, in one retrospective study of 201 pregnant women undergoing thyroid or parathyroid surgery (92 women underwent thyroidectomy for thyroid cancer), pregnant women had significantly higher rates of surgical complications (11 versus 4 percent) and endocrine-specific complications (16 versus 8 percent) than nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/74\">",
"     74",
"    </a>",
"    ]. Endocrine-specific complications were defined as maternal hypoparathyroidism, hypocalcemia, or recurrent laryngeal nerve injury. In this study, 50 of the 201 procedures were considered to be",
"    <span class=\"nowrap\">",
"     emergent/urgent",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/74\">",
"     74",
"    </a>",
"    ]. Higher surgeon volume was a predictor of lower complication rates. Thus, when surgery is required during the second trimester, it should be performed only by expert thyroid surgeons. The risks of nonobstetric surgery during pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=see_link\">",
"     \"Management of pregnant women undergoing nonobstetric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57692128\">",
"    <span class=\"h2\">",
"     Previously treated",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women previously treated with radioiodine for thyroid cancer, pregnancy should be delayed for at least six months to ensure that thyroid hormone levels have normalized and that additional radiation treatment is not required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=see_link&amp;anchor=H2003100#H2003100\">",
"     \"Radioiodine treatment of differentiated thyroid cancer\", section on 'Future pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women without ultrasound or biochemical (thyroglobulin) evidence of persistent disease, pregnancy itself has not been shown to increase the risk of recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. However, in women with persistent disease (structural or biochemical), disease progression may occur during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/75,77\">",
"     75,77",
"    </a>",
"    ]. In women who have persistently elevated thyroglobulin levels or evidence of persistent disease on ultrasound prior to pregnancy, periodic ultrasound and thyroglobulin (once each trimester) monitoring is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During pregnancy, thyroid hormone suppression therapy should continue, and preconception TSH goals should remain the same. To maintain the same degree of TSH suppression, most women will require an increase in dose. Thus, TSH should be measured as soon as pregnancy is confirmed and every four weeks until 16 to 20 weeks of gestation, and then at least once between 26 and 32 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"     9",
"    </a>",
"    ]. The dose of thyroxine should be increased to maintain TSH in the desired range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Thyroid hormone suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSTPARTUM THYROID DYSFUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Postpartum thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of postpartum thyroiditis varies globally and ranges from 1 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/44,78,79\">",
"     44,78,79",
"    </a>",
"    ]. Higher rates, up to 25 percent, have been reported in women with type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/78\">",
"     78",
"    </a>",
"    ], and the highest rates occur among women with a prior history of postpartum thyroiditis (pooled prevalence 42 percent) and in women with positive antithyroid peroxidase antibodies who had normal thyroid function during pregnancy (40 to 60 percent compared with 0 to 5 percent of women without antibodies) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/78\">",
"     78",
"    </a>",
"    ]. It may occur after pregnancy loss (miscarriage, abortion, ectopic pregnancy), as well as after normal delivery. Postpartum thyroid dysfunction can occur in women already taking thyroid hormone replacement for hypothyroidism antedating pregnancy (eg, goitrous Hashimoto's thyroiditis), if they have some remaining thyroid tissue capable of producing thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two patterns of postpartum dysfunction can be defined: postpartum thyroiditis and a postpartum exacerbation of chronic lymphocytic (Hashimoto's) thyroiditis. Postpartum thyroiditis is characterized by transient hyperthyroidism, or transient hyperthyroidism followed by transient or rarely permanent hypothyroidism. Postpartum exacerbation of Hashimoto's thyroiditis is characterized by postpartum progression of autoimmune destruction. It may cause a transient or permanent increase in thyroid hormone requirements. In one study, for example, more than 50 percent of women with Hashimoto&rsquo;s thyroiditis required an increase in their pregestational dose thyroxine dose in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of postpartum thyroiditis are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link\">",
"     \"Postpartum thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women may develop Graves' disease postpartum or experience an exacerbation. In addition, women in remission after antithyroid drug therapy have a higher incidence of relapse during the postpartum period than at times unrelated to pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link&amp;anchor=H17#H17\">",
"     \"Hyperthyroidism during pregnancy: Treatment\", section on 'Postpartum issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=see_link\">",
"       \"Patient information: Thyroiditis after pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=see_link\">",
"       \"Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are largely consistent with Guidelines on the Management of Thyroid Disease During Pregnancy and Postpartum from the American Thyroid Association (ATA) and Endocrine Society [",
"    <a class=\"abstract\" href=\"UTD.htm?15/51/16186/abstract/9,44\">",
"     9,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590665\">",
"    <span class=\"h2\">",
"     Thyroid physiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To meet the increased metabolic needs during a normal pregnancy, there are changes in thyroid physiology that are reflected in altered thyroid function tests. The major changes in thyroid function during pregnancy are an increase in serum thyroxine-binding globulin (TBG) concentrations and stimulation of the thyrotropin (TSH) receptor by chorionic gonadotropin (hCG). Together, these changes lead to an increase in both serum total thyroxine (T4) and triiodothyronine (T3) concentrations and a reduction in serum TSH. Serum free T4 and T3 concentrations initially increase slightly, usually within the normal range. With advancing gestational age, particularly between the first and second trimester, free T4 concentrations decrease gradually. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thyroid adaptation during normal pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the changes in thyroid physiology during normal pregnancy, thyroid function tests should be interpreted using trimester-specific TSH and T4 reference ranges for pregnant women. If the laboratory does not provide trimester-specific reference ranges for TSH",
"      <span class=\"nowrap\">",
"       (mU/L),",
"      </span>",
"      the following reference ranges can be used for the first, second, and third trimester, respectively: 0.1 to 2.5, 0.2 to 3.0, and 0.3 to 3.0",
"      <span class=\"nowrap\">",
"       mU/L.",
"      </span>",
"      Total T4 and total T3 levels during pregnancy are 1.5-fold higher than in nonpregnant women. Reference ranges for free T4 are method-specific, and trimester-specific reference ranges should be provided with the assay kits. (See",
"      <a class=\"local\" href=\"#H1156384\">",
"       'Trimester-specific reference ranges'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590649\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthyroidism from any cause can complicate pregnancy, but Graves' hyperthyroidism is the most common cause of overt hyperthyroidism. hCG-mediated hyperthyroidism is a common cause of subclinical hyperthyroidism. It may occur transiently in the first half of gestation and is typically less severe than Graves&rsquo; disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hyperthyroidism complicating pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link&amp;anchor=H12186870#H12186870\">",
"       \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\", section on 'Establishing the cause'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of hyperthyroidism during pregnancy should be based primarily upon a suppressed (&lt;0.1",
"      <span class=\"nowrap\">",
"       mU/L)",
"      </span>",
"      or undetectable (&lt;0.01) serum TSH value and also a serum free T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      free T3 (or total T4",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      total T3) measurement that exceeds the normal range during pregnancy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment options for pregnant women with hyperthyroidism are reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"       \"Hyperthyroidism during pregnancy: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590657\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When iodine nutrition is adequate (as in the US), the most common cause of hypothyroidism during pregnancy is chronic autoimmune (Hashimoto&rsquo;s) thyroiditis. In iodine deficient areas, iodine deficiency itself is associated with hypothyroidism and goiter. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Hypothyroidism during pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of overt primary hypothyroidism during pregnancy is based upon the finding of a decreased free T4 concentration (below assay normal using reference range for pregnant women) and an elevated trimester-specific serum TSH. Subclinical hypothyroidism is defined as an elevated trimester-specific serum TSH concentration with a normal free T4 concentration. (See",
"      <a class=\"local\" href=\"#H1156783\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693645#H57693645\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The universal screening of asymptomatic pregnant women for hypothyroidism during the first trimester of pregnancy is controversial. We suggest a targeted approach rather than universal screening (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We favor screening pregnant women if they are from an area of moderate to severe iodine insufficiency, have symptoms of hypothyroidism, a family or personal history of thyroid disease, or a personal history of thyroid peroxidase antibodies, type 1 diabetes, morbid obesity, head and neck radiation, recurrent miscarriage, or infertility. In women who meet the screening criteria, we measure serum TSH during the first trimester. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Screening'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693652#H57693652\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of newly diagnosed and preexisting hypothyroidism is reviewed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link&amp;anchor=H57693659#H57693659\">",
"       \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590732\">",
"    <span class=\"h2\">",
"     Thyroid peroxidase antibodies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased rate of fetal loss and premature delivery has been reported in euthyroid women with high serum antithyroid peroxidase (TPO) antibody concentrations. Although data are conflicting,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41656?source=see_link\">",
"       levothyroxine",
"      </a>",
"      treatment of TPO antibody positive pregnant patients may lower these risks. Since carefully monitored thyroid hormone treatment is safe, until additional data become available, we suggest thyroid hormone treatment (T4, 50 mcg daily) in euthyroid TPO positive women who have had recurrent miscarriage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, other experts, including other UpToDate editors, do not routinely treat euthyroid TPO positive women with T4 because of insufficient evidence of benefit. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Thyroid peroxidase antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Euthyroid women with high serum TPO antibody concentrations are at risk for developing hypothyroidism. In antibody positive euthyroid pregnant women who are not treated with thyroid hormone, TSH should be measured every four weeks during the first half of pregnancy and at least once during the last trimester. Thyroid hormone should be initiated if TSH rises above the trimester-specific reference range (2.5",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      for first, and 3.0",
"      <span class=\"nowrap\">",
"       mU/L",
"      </span>",
"      for second and third trimesters). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Thyroid peroxidase antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590680\">",
"    <span class=\"h2\">",
"     Goiter and thyroid nodules",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Goiter during pregnancy is rare in the United States. However, goiter during pregnancy is common in regions where iodine intake is low, occurring in 16 to 70 percent of women in iodine-deficient regions of Western Europe. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Goiter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pregnant woman found to have a thyroid nodule should be evaluated in the same way as if she were not pregnant, except that thyroid radionuclide scanning is contraindicated. (See",
"      <a class=\"local\" href=\"#H590601\">",
"       'Thyroid nodules'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Thyroid cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H590688\">",
"    <span class=\"h2\">",
"     Thyroiditis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpartum thyroiditis occurs in 5 to 10 percent of women in the United States. It may occur after pregnancy loss (miscarriage, abortion, ectopic pregnancy), as well as after normal delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=see_link\">",
"       \"Postpartum thyroiditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/1\">",
"      Glinoer D. The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. Endocr Rev 1997; 18:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/2\">",
"      Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987; 65:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/3\">",
"      Ballabio M, Poshychinda M, Ekins RP. Pregnancy-induced changes in thyroid function: role of human chorionic gonadotropin as putative regulator of maternal thyroid. J Clin Endocrinol Metab 1991; 73:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/4\">",
"      Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab 1995; 80:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/5\">",
"      Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/6\">",
"      Yeo CP, Khoo DH, Eng PH, et al. Prevalence of gestational thyrotoxicosis in Asian women evaluated in the 8th to 14th weeks of pregnancy: correlations with total and free beta human chorionic gonadotrophin. Clin Endocrinol (Oxf) 2001; 55:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/7\">",
"      Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/8\">",
"      Lockwood CM, Grenache DG, Gronowski AM. Serum human chorionic gonadotropin concentrations greater than 400,000 IU/L are invariably associated with suppressed serum thyrotropin concentrations. Thyroid 2009; 19:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/9\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/10\">",
"      Dashe JS, Casey BM, Wells CE, et al. Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. Obstet Gynecol 2005; 106:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/11\">",
"      Stricker R, Echenard M, Eberhart R, et al. Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. Eur J Endocrinol 2007; 157:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/12\">",
"      Gilbert RM, Hadlow NC, Walsh JP, et al. Assessment of thyroid function during pregnancy: first-trimester (weeks 9-13) reference intervals derived from Western Australian women. Med J Aust 2008; 189:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/13\">",
"      Fitzpatrick DL, Russell MA. Diagnosis and management of thyroid disease in pregnancy. Obstet Gynecol Clin North Am 2010; 37:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/14\">",
"      Lambert-Messerlian G, McClain M, Haddow JE, et al. First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. Am J Obstet Gynecol 2008; 199:62.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/15\">",
"      Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2009; 200:260.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/16\">",
"      Soldin OP, Tractenberg RE, Hollowell JG, et al. Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. Thyroid 2004; 14:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/17\">",
"      Kahric-Janicic N, Soldin SJ, Soldin OP, et al. Tandem mass spectrometry improves the accuracy of free thyroxine measurements during pregnancy. Thyroid 2007; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/18\">",
"      Yue B, Rockwood AL, Sandrock T, et al. Free thyroid hormones in serum by direct equilibrium dialysis and online solid-phase extraction--liquid chromatography/tandem mass spectrometry. Clin Chem 2008; 54:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/19\">",
"      Leung AM, Pearce EN, Braverman LE. Iodine content of prenatal multivitamins in the United States. N Engl J Med 2009; 360:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/20\">",
"      Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994; 331:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/21\">",
"      Vulsma T, Gons MH, de Vijlder JJ. Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989; 321:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/22\">",
"      Bajoria R, Fisk NM. Permeability of human placenta and fetal membranes to thyrotropin-stimulating hormone in vitro. Pediatr Res 1998; 43:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/23\">",
"      Roti E, Gnudi A, Braverman LE, et al. Human cord blood concentrations of thyrotropin, thyroglobulin, and iodothyronines after maternal administration of thyrotropin-releasing hormone. J Clin Endocrinol Metab 1981; 53:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/24\">",
"      Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010; 31:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/25\">",
"      Davis LE, Lucas MJ, Hankins GD, et al. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1989; 160:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/26\">",
"      Sheffield JS, Cunningham FG. Thyrotoxicosis and heart failure that complicate pregnancy. Am J Obstet Gynecol 2004; 190:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/27\">",
"      Casey BM, Dashe JS, Wells CE, et al. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006; 107:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/28\">",
"      American College of Obstetricians and Gynecologists.. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstet Gynecol 2002; 100:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/29\">",
"      Abalovich M, Gutierrez S, Alcaraz G, et al. Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002; 12:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/30\">",
"      Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999; 50:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/31\">",
"      Hallengren B, Lantz M, Andreasson B, Grennert L. Pregnant women on thyroxine substitution are often dysregulated in early pregnancy. Thyroid 2009; 19:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/32\">",
"      LaFranchi SH, Haddow JE, Hollowell JG. Is thyroid inadequacy during gestation a risk factor for adverse pregnancy and developmental outcomes? Thyroid 2005; 15:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/33\">",
"      Leung AS, Millar LK, Koonings PP, et al. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol 1993; 81:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/34\">",
"      Wasserstrum N, Anania CA. Perinatal consequences of maternal hypothyroidism in early pregnancy and inadequate replacement. Clin Endocrinol (Oxf) 1995; 42:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/35\">",
"      Davis LE, Leveno KJ, Cunningham FG. Hypothyroidism complicating pregnancy. Obstet Gynecol 1988; 72:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/36\">",
"      Stagnaro-Green A, Chen X, Bogden JD, et al. The thyroid and pregnancy: a novel risk factor for very preterm delivery. Thyroid 2005; 15:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/37\">",
"      Pop VJ, Kuijpens JL, van Baar AL, et al. Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. Clin Endocrinol (Oxf) 1999; 50:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/38\">",
"      Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/39\">",
"      Idris I, Srinivasan R, Simm A, Page RC. Maternal hypothyroidism in early and late gestation: effects on neonatal and obstetric outcome. Clin Endocrinol (Oxf) 2005; 63:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/40\">",
"      Allan WC, Haddow JE, Palomaki GE, et al. Maternal thyroid deficiency and pregnancy complications: implications for population screening. J Med Screen 2000; 7:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/41\">",
"      Klein RZ, Haddow JE, Faix JD, et al. Prevalence of thyroid deficiency in pregnant women. Clin Endocrinol (Oxf) 1991; 35:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/42\">",
"      Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/43\">",
"      Committee on Patient Safety and Quality Improvement, Committee on Professional Liability. ACOG Committee Opinion No. 381: Subclinical hypothyroidism in pregnancy. Obstet Gynecol 2007; 110:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/44\">",
"      De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/45\">",
"      Horacek J, Spitalnikova S, Dlabalova B, et al. Universal screening detects two-times more thyroid disorders in early pregnancy than targeted high-risk case finding. Eur J Endocrinol 2010; 163:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/46\">",
"      Bussen S, Steck T. Thyroid autoantibodies in euthyroid non-pregnant women with recurrent spontaneous abortions. Hum Reprod 1995; 10:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/47\">",
"      Prummel MF, Wiersinga WM. Thyroid autoimmunity and miscarriage. Eur J Endocrinol 2004; 150:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/48\">",
"      M&auml;nnist&ouml; T, V&auml;&auml;r&auml;sm&auml;ki M, Pouta A, et al. Perinatal outcome of children born to mothers with thyroid dysfunction or antibodies: a prospective population-based cohort study. J Clin Endocrinol Metab 2009; 94:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/49\">",
"      Chen L, Hu R. Thyroid autoimmunity and miscarriage: a meta-analysis. Clin Endocrinol (Oxf) 2011; 74:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/50\">",
"      Thangaratinam S, Tan A, Knox E, et al. Association between thyroid autoantibodies and miscarriage and preterm birth: meta-analysis of evidence. BMJ 2011; 342:d2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/51\">",
"      Negro R, Formoso G, Mangieri T, et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006; 91:2587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/52\">",
"      Toulis KA, Goulis DG, Venetis CA, et al. Risk of spontaneous miscarriage in euthyroid women with thyroid autoimmunity undergoing IVF: a meta-analysis. Eur J Endocrinol 2010; 162:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/53\">",
"      Negro R, Mangieri T, Coppola L, et al. Levothyroxine treatment in thyroid peroxidase antibody-positive women undergoing assisted reproduction technologies: a prospective study. Hum Reprod 2005; 20:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/54\">",
"      Ghassabian A, Bongers-Schokking JJ, de Rijke YB, et al. Maternal thyroid autoimmunity during pregnancy and the risk of attention deficit/hyperactivity problems in children: the Generation R Study. Thyroid 2012; 22:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/55\">",
"      Smyth PP, Hetherton AM, Smith DF, et al. Maternal iodine status and thyroid volume during pregnancy: correlation with neonatal iodine intake. J Clin Endocrinol Metab 1997; 82:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/56\">",
"      Rasmussen NG, Hornnes PJ, Heged&uuml;s L. Ultrasonographically determined thyroid size in pregnancy and post partum: the goitrogenic effect of pregnancy. Am J Obstet Gynecol 1989; 160:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/57\">",
"      Rotondi M, Amato G, Biondi B, et al. Parity as a thyroid size-determining factor in areas with moderate iodine deficiency. J Clin Endocrinol Metab 2000; 85:4534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/58\">",
"      Berghout A, Wiersinga W. Thyroid size and thyroid function during pregnancy: an analysis. Eur J Endocrinol 1998; 138:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/59\">",
"      Kung AW, Chau MT, Lao TT, et al. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab 2002; 87:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/60\">",
"      Glinoer D, Soto MF, Bourdoux P, et al. Pregnancy in patients with mild thyroid abnormalities: maternal and neonatal repercussions. J Clin Endocrinol Metab 1991; 73:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/61\">",
"      Karger S, Sch&ouml;tz S, Stumvoll M, et al. Impact of pregnancy on prevalence of goitre and nodular thyroid disease in women living in a region of borderline sufficient iodine supply. Horm Metab Res 2010; 42:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/62\">",
"      Tan GH, Gharib H, Goellner JR, et al. Management of thyroid nodules in pregnancy. Arch Intern Med 1996; 156:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/63\">",
"      Marley EF, Oertel YC. Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women. Diagn Cytopathol 1997; 16:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/64\">",
"      Rosen IB, Walfish PG, Nikore V. Pregnancy and surgical thyroid disease. Surgery 1985; 98:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/65\">",
"      Smith LH, Danielsen B, Allen ME, Cress R. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am J Obstet Gynecol 2003; 189:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/66\">",
"      Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab 1997; 82:2862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/67\">",
"      Yasmeen S, Cress R, Romano PS, et al. Thyroid cancer in pregnancy. Int J Gynaecol Obstet 2005; 91:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/68\">",
"      Herzon FS, Morris DM, Segal MN, et al. Coexistent thyroid cancer and pregnancy. Arch Otolaryngol Head Neck Surg 1994; 120:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/69\">",
"      Monroy-Lozano BE, Hurtado-L&oacute;pez LM, Zaldivar-Ram&iacute;rez FR, Basurto-Kuba E. [Clinical behavior of thyroid papillary cancer in pregnancy: optimal time for its treatment]. Ginecol Obstet Mex 2001; 69:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/70\">",
"      Alves GV, Santin AP, Furlanetto TW. Prognosis of thyroid cancer related to pregnancy: a systematic review. J Thyroid Res 2011; 2011:691719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/71\">",
"      Nam KH, Yoon JH, Chang HS, Park CS. Optimal timing of surgery in well-differentiated thyroid carcinoma detected during pregnancy. J Surg Oncol 2005; 91:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/72\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/73\">",
"      Chong KM, Tsai YL, Chuang J, et al. Thyroid cancer in pregnancy: a report of 3 cases. J Reprod Med 2007; 52:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/74\">",
"      Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 2009; 144:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/75\">",
"      Leboeuf R, Emerick LE, Martorella AJ, Tuttle RM. Impact of pregnancy on serum thyroglobulin and detection of recurrent disease shortly after delivery in thyroid cancer survivors. Thyroid 2007; 17:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/76\">",
"      Ros&aacute;rio PW, Barroso AL, Purisch S. The effect of subsequent pregnancy on patients with thyroid carcinoma apparently free of the disease. Thyroid 2007; 17:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/77\">",
"      Hirsch D, Levy S, Tsvetov G, et al. Impact of pregnancy on outcome and prognosis of survivors of papillary thyroid cancer. Thyroid 2010; 20:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/78\">",
"      Nicholson WK, Robinson KA, Smallridge RC, et al. Prevalence of postpartum thyroid dysfunction: a quantitative review. Thyroid 2006; 16:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/79\">",
"      Stagnaro-Green A. Postpartum thyroiditis. Best Pract Res Clin Endocrinol Metab 2004; 18:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/80\">",
"      Caix&agrave;s A, Albareda M, Garc&iacute;a-Patterson A, et al. Postpartum thyroiditis in women with hypothyroidism antedating pregnancy? J Clin Endocrinol Metab 1999; 84:4000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/51/16186/abstract/81\">",
"      Galofr&eacute; JC, Haber RS, Mitchell AA, et al. Increased postpartum thyroxine replacement in Hashimoto's thyroiditis. Thyroid 2010; 20:901.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7851 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-5846377118-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16186=[""].join("\n");
var outline_f15_51_16186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THYROID ADAPTATION DURING NORMAL PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1156377\">",
"      Thyroid physiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H994015\">",
"      - Thyroxine binding globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H994022\">",
"      - hCG and thyroid function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1156384\">",
"      Trimester-specific reference ranges",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1156391\">",
"      Iodine requirements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      THYROID FUNCTION IN THE FETUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HYPERTHYROIDISM COMPLICATING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16385488\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fetal and neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HYPOTHYROIDISM DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57694701\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1156783\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1156716\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      THYROID PEROXIDASE ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      GOITER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590601\">",
"      THYROID NODULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THYROID CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57692121\">",
"      Diagnosed during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57692128\">",
"      Previously treated",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSTPARTUM THYROID DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590665\">",
"      Thyroid physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590649\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590657\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590732\">",
"      Thyroid peroxidase antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590680\">",
"      Goiter and thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H590688\">",
"      Thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24452?source=related_link\">",
"      Atlas of thyroid cytopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26679?source=related_link\">",
"      Evaluation of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=related_link\">",
"      Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=related_link\">",
"      Iodine deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3608?source=related_link\">",
"      Laboratory assessment of thyroid function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/5/37976?source=related_link\">",
"      Management of couples with recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15482?source=related_link\">",
"      Management of pregnant women undergoing nonobstetric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/58/13219?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/54/15203?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/54/3938?source=related_link\">",
"      Patient information: Hypothyroidism (underactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/50/5922?source=related_link\">",
"      Patient information: Thyroiditis after pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/248?source=related_link\">",
"      Postpartum thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34010?source=related_link\">",
"      Radioiodine treatment of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15081?source=related_link\">",
"      Treatment and prognosis of congenital hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_51_16187="Estimates of nutritional status in HD pts";
var content_f15_51_16187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimates of nutritional status in hemodialysis patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        P value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin, g/dL",
"       </td>",
"       <td>",
"        4.5&plusmn;0.2",
"       </td>",
"       <td>",
"        3.9&plusmn;0.4",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transferrin, mg/dL",
"       </td>",
"       <td>",
"        303&plusmn;41",
"       </td>",
"       <td>",
"        208&plusmn;57",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG, mg/dL",
"       </td>",
"       <td>",
"        1139&plusmn;338",
"       </td>",
"       <td>",
"        1008&plusmn;345",
"       </td>",
"       <td>",
"        &lt;0.05",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Plasma levels of albumin, transferrin, and IgG in normal subjects and 30 stable hemodialysis patients. In the absence of volume expansion or low iron stores, low albumin and transferrin levels are suggestive of malnutrition.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Wolfson, M, Strong, CJ, Minturn, D, et al, Am J Clin Nutr 1984; 39:547.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16187=[""].join("\n");
var outline_f15_51_16187=null;
var title_f15_51_16188="CAM discussion points";
var content_f15_51_16188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to talk with caregivers/patients about complementary and alternative therapies for children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Do",
"        </strong>",
"        talk about the different kinds of therapies families may have tried to help their child.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do",
"        <strong>",
"         not",
"        </strong>",
"        wait for families to bring it up.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask in an open-minded, non-judgmental fashion. Avoid using potentially pejorative terms such as \"unproven,\" \"unconventional,\" or \"alternative.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Elicit further information with questions about specific therapies:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Have you tried any",
"        <strong>",
"         herbal",
"        </strong>",
"        therapies, such as echinacea or ginkgo?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Have you tried any",
"        <strong>",
"         dietary",
"        </strong>",
"        therapies, like avoiding wheat or milk?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Have you sought care from any",
"        <strong>",
"         other health professionals",
"        </strong>",
"        , such as acupuncturists or chiropractors?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Elicit the values, beliefs, and influences that led parents to these therapies:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Suggested by family members?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Consistent with their religious, spiritual, or cultural beliefs?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Value of natural or organic approaches?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Fear of side effects of mainstream treatments?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whenever possible, join with the parents and support their decision to pursue avenues that may help their child; be an ally rather than a tyrant.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask how well the family thinks the therapies worked or didn't work",
"        <strong>",
"         before",
"        </strong>",
"        offering your opinion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer to talk with other therapists involved in the child's care to better maintain coordinated, comprehensive care.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer to learn more to help answer the family's questions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer families additional information and resources to address their questions about alternative and complementary therapies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16188=[""].join("\n");
var outline_f15_51_16188=null;
var title_f15_51_16189="Canadian Neurological Scale";
var content_f15_51_16189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Canadian Neurological Scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"3\">",
"        Patient Name:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Rater Name:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Date:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Time:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Mentation",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Level consciousness",
"       </td>",
"       <td>",
"        Alert",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drowsy",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Orientation",
"       </td>",
"       <td>",
"        Oriented",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disoriented/NA",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Speech",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Expressive deficit",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Receptive deficit",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        TOTAL:&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Motor functions (no comprehension deficit)",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Weakness",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Face",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        0.0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Arm: proximal",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Arm: distal",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Leg",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        TOTAL:&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Motor response (comprehension deficit)",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Face",
"       </td>",
"       <td>",
"        Symmetrical",
"       </td>",
"       <td>",
"        .5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymmetrical",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Arms",
"       </td>",
"       <td>",
"        Equal",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unequal",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Legs",
"       </td>",
"       <td>",
"        Equal",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unequal",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        TOTAL:&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: C&ocirc;t&eacute; R, Hachinski VC, Shurvell BL, et al. The Canadian Neurological Scale: a preliminary study in acute stroke. Stroke 1986; 17:731. Copyright &copy; 1986 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16189=[""].join("\n");
var outline_f15_51_16189=null;
var title_f15_51_16190="Womens health initiative risk of stroke";
var content_f15_51_16190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F74704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F74704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Women's Health Initiative: Risk of stroke",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 307px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of cumulative hazard rates of stroke. In the Women's Health Initiative, combined estrogen-progestin therapy was associated with a significant increase in stroke when compared with placebo. The intention-to-treat hazard ratio was 1.31, 95% CI 1.02-1.68.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wassertheil-Smoller S, Hendrix S, Limacher M, et al. Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women's Health Initiative: A Randomized Trial. JAMA 2003; 289:2673.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16190=[""].join("\n");
var outline_f15_51_16190=null;
var title_f15_51_16191="Gram stain sputum 5 with answer";
var content_f15_51_16191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moraxella catarrhalis in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCKO3ERzwScHGPbkY/z/WmyEkZxgj2q95HTPT2qtcQhQSPr9TXgI9Ez/MYSHcSRnPIwamE7eYBGAVHJyelUbmNiwIZgKgW42vtJP0q1EdzfivQCSwwo4+tXrafew3bVcjOM/wCf8muXGXfAfA71vWEg8sA8471Eo22KdrXNVHDAHDAEZywx6YqJx84AADHnt+NNcxxqGZyv+ypwD/n2qGSd5F2qCAe/eoSJjFshkYmXy4x8o+8ScjrSsAoyM7fUk1Yhj8pMYxzk570SoG5Az60y3o7IrlwvZxjjkHFOST5MhSBjpxTS8eRGSS3Iz6U9sq21eST6UCsTblK8rnP6Gkzg7Qo2kAEnqf8AHvSEbR1/CkY4j+bgdC3vSFbUsgdB68e9LIo2kqOvr2qKDCoMD6CpJZAF6ZJPAzSC2o5cNsJxjPTFMnCcsVI7VKowoKZyf0qKY4jyzBfc0rDRlEgXGEVmbHTPX14z2zUkhMzgSg4GOKdEm8swySB3pu2VuSpHParNpOz0IrkFmHlxjvjFU7t0kBSXMjRknYDnketWdQl+zxbt4DnpUWnx3EsBZoyGcdcckUNWRpTulzMzNPDTvLKy7M1cW23EMH3cfdB9zUawMjsqsVycCtKzhjt4Sd25h1xSbszeq7q6GGIKyllw2B3/AK0gnSNnSMDJHUVcSWGeM4PzdMVXuLWMKzqSCvNO/c5o6v3jOgth5omPMkZyBmp5UkMu5UbbjPJwc0y3lQzZ5TPFaitCX2pINyjGaet7s0nKxbt7kyRBQCHXAOR0qRJgmUlO30PNV/Mc5UDaWHpS/Zg+xXm3gHJB7VOhzOKHXM8kXCKNzc8cgfhUaTllV3BD9+McVZlkWN18srJ/OmXIk2q4jKnPIzRcEl2GFGaBCoyE7nk1DcBmXeCgkXv7f5/wq9G0YQ4mHAyVzUUssLgBYwc98U0K/QlKsrcEDnn1qA7PPbLyEgdOcD8OlSSHci7RtNSw/MBwNw68c0E7akNskZBHynIJA7+1QpCXeUt0zkBulR3p8uT5VZSGyCO9PiugJvnAG4daduxXK7XROF8wbWXrnGT1Hc/rVK8V9rQCNZVYfxcD/PFaasGJ2kEdiDVW7kYTQxxoXbvRHciO+oyCziEUZVflxkDsKkHyZwgUew7/AOcVIhjSM8gDvzio7WRZI32HnOcHrTRLuyvckeeqKODyCMZqlqNnBqFjPZXB2rKpXkDIznBHHXrzz0rU2ByXYAEcc1Qux+7kJUg4IDgcj6VSfYXLc8x/4Q2P/p//AO/a/wCNFehfZ5v+fqT/AL5Wit/rFTuP2cToSM4zn8aikhVk5ySO/U1I+dwweRSoSD82MZ4rkBGRPa4PTFZVzY7TuVcH1rrJIg3vVea3DduKuM7AcrBG6Hnqa1rVzGgyef1qy9mvUj9aQW4XOFye1U2mNNCbw7qzbuPcgflV6NSdrAfiaq28QDAsCSKt5JXGOB+tZy1Zo5aWRIyPIPvcmhY9q9TUXmZUAH5ugFPVisR8wjNJk2Y1oo8bwvIPB9KOp3DqBToWLqMkYbleev0p5XK9qQN2K53HO4YGcA+tQPbA3EbuxIXoBVtueP5VHMoK8nA6VQk9RxnUNkj6YoBMjZAwMcHj/wDXVYBXIVTk96tDgA4wKRT0HiRmB2nHbpUcjblw/IxwKcGG7aW59MVHHCdxJJJzRsCHw4EXPA/KklmVYyY1yR61IWKgAhdo61Wu5VEQKhQ7dMUkUlzMoW9nJd6gJLoZQHIWtmQ/ZkZ2+VRwDmqa28lrCtwspdmHKf5PNV71LrUJVjjB8rAYD1GKejd29Db+JK3RDNKtxNPPJcN8rHKn0qSYRW7vtO9B6H8arJctYx+SsIkd+Dn+GsDXtcXTkW1tsPcynLqei0WcpadTsp0nOXkbsF7E8TuxCsCeBTbO7iMTM0jSbjwK4a31Jnm2yMNpPOKv2hKMXR90ZPaqceW6Z2ywKtdHbW3kXUZVYwpxznrVZ5oLOX5hlgeoGfzNVLG4QyqydXPatiSxilg2bVeR+RkDr9cZqU0jy6tNwdmTQpIIhcSuCrDK1m3N0fMXYxAPU4qWwhu1E0NwQEB+QHsKmks1MO1hlzTvZkxUU9SOzuIkhd5mxIp+UirhnmkRTuzHjjIrn7mB45gqkhe5NbGi3CurQ3OW9D6UPa5VWCS5hbaEyCRmb5yewxVgxzK6oRlB6DpUckiwXGxhz2I71ZikIhLZDDFK5hJvcdJbscc/L9etMkvIrGAPIWC/xYXJ/KkhusxDzMrk8VJLEkgbfFHLEevmKCB+dHqZNPZlWSWSUC5AQwNyo7n8KgN0ZZg7wqyn5QKlZo7hzBARtjGAFpgKxW/zKQwPAPWmbKyWw6GCWBiGZjk5wD0FWI7lGmZEVhIF6sKW0vYpZ1jAxKVyAfWp5oeWPRmPXND7SMpS11RUaBxp06zttcnKuOMc1PBEkNvEobLkYyT1PJ78nilubcz27IW/LvTLdm8oJuyUO2i90Q3dEd9JhMD73pQ432yl12nbjGev+PSkv0LIpwCwOajjnEgADfMCDjJH5+3FO2hNvduiP7JH/wA8pP0oqbLf34/++v8A61FF2F33LC5c8nC9xUpYA5J7cVWLFRnvmnI4CKWIXPGT3NQx2LKOAAT16U5sD73Ujp3qEAHv170qkBhk0AkmK6knpx2puxRn1NP3nbx602b7uT0A7U7isQsu05XjNRk49SfQVIckZB4xn6UI/HIxincpDAhZeAd1R3EotYC83znOFXH3j7+3TP5VZR8Au3QVWvFFxc2bqcCNtxHryD/SkUm9g02ykdvtd27GVhkR4xtHbP8AQCrhXGRzwKfAxJ+Ylm6k5ySaewDZBOKV7sh7kPXPSq0yrkgnj0rREKhepzVW5t+QU/WmmEWrlVYguGjYKPSpgGBwTSrHs+UDk08xMeWY0FMSIDcASN3bipgBzwM9qZHBkhs4bpmnEMGweppCZHLkRs2eDUCQiRAxzuPQntVnYen9ap3kxjkMcZ+cjnHShamkL7Itp8iMJGUrjGKz7CdobmQy5CtwvrVhbcpAXYlnfp6UtqbdYt7nEg7mjSxcbK/UpI32OSa8kgaWKMFjmvJtTup7u6uLoxkeY+QT2r2WGRpZWt+TFKpB968k1C3/ANPurdZgIlkIJbtW1BpTlda6fcetg4upHlW5mwK0Z4yzHritXS2nVHVt2CeKgihtrUH/AEkzP2ArQs5GmXcn8I5Fa1Z3Wx6dKh7OOr17XuadhKYypLHce1b1rc3kQG0sSe5rnbYl5lOMFe9dxoUiz2MSvtDDNcsm0ebjOWKvYdErt843M2MsTUivHcTjOQVHHuauEiKUJGQWY4IFMli8i5EzEKncGkjyedN3KzLG8nlzoFBHWnW8a25bauUPfvUV+VnlEqE/L3qeGLdHGQ4KjqM0WCUtNR13bLOrMxwAOOetVBkACNjgcYPer7xQSORKdrexqs9nBPL5UczfL6U72FCStZkN7G72yqgAYHOe1QQW93fOqXE8i24/gjHX8auT2yRyRrIW2qMkk9aSKO5luI0t5di+oNUpWW5V9NC9bWdvaZSCMKw6sTyfrVG5MsuprbwrHKm35nB+6abYGWG9uobhwzn37VpWcAjDlVBLd+pNJ6PuYtuDuyjb2LRt5zTJlRjHpVyBh5YDMS2ep71WksXLvtYqD71IbeX5Ejm2MvJwSP5UXFN82rY+Uyxys4OYwORVDSbyC9uboWtxG7R8ugPStO8ZY7aViCcA1g+G9As9NM93bF2muuWyeFFNNcrvv0/4IK3LdmjIu67VgSV24Ipjx/O7oypj0qZ3VIxkEn2qlevcRMJIIy69CrH9afUhJvQfuh/56L+QoqH7T/0zb/vmilYfIW+S/WnuWYYIOB6HpSqpP4U1I380sx+QHpSBDpJGXAUYHbmnRZZsikdC33RxU0ERjT53LA85IpMaaSEV+dpU4o3E4ODipEdWJHA9qazYIB6k9qQhgzznvUUrIq9s1OWXPzY57n0qndCMPkfNmmhxVzG1671VfLTTIgY8ZY+9XNCa6exU34xPk8d8e9WcZXKnAHpVSGf98U7561WrXLZafebOaceVI11k2MOxPFTqTuz3PaqCZdsn86sqWDjJ4/lU2MGWw3XkVC+77wP4UyRiAcDioN52Hn8KNgUbliObOd3PapEcHHQCqcYbAqwi7gOBikNpEsrsANvemq8jvhqftGMMCaeDt9KLi2Qu3b90E89vSsy4USzkquWHcVbuJ2IIUEUW0KlSoGB3Io2HG8dWRW8hIZJlI9B6VUgtXjLmQkqTxmtFYsSfNwOnFOeEum3+HtRexanZleS1PlNIjskwXCEdK8Xv7W4ttRuPtsTnc56gjPvXtayzwMAwDxY9M1m+ILWz1G1UvbPM+egOKqnUlTd0rpndhKyjLlmeNweSqSFWw2cAVoaY7wzKI23B+CK6MeB/tNyWhTywOcMeBWrp/gswvHL5yZjIJBzWtTE05Kx6cKsKWsmtOxU023JujFJGQSuRXZaRbxQpgr146dKzbyD7JIk4TLdB702z8QHzpUmtyPK9BXOouSuefiZyrr3dixrMEkEjXMEhCp87YPYdq5iTxTd65eLahFjjHEeDyT61J4i1a5vFkijQwQy53Z6sKpeFtEkM4umbai/dHc1qmoxbnv0NqVBRp81Q7Gys3iKrcShiByua1okiSMsoK+x7Vn2dvIZDO5OehNT3iyM6CLkk4P0rNXe55dX3pbjLqCSZcwsF9WPaqt4Wsdiof3h4MgrRkhlZcM+OO1Zc16sXmRz4IzgetUmFO70JLtwEkZpDLgZ4rO06/Ml3B/rI0c4BNZsl/Kt8+6N/IIwqgdfxpywXEaC6mU+XyUB7CqtbfqdkaS5bM3LuzUXpf7QTIWyTmo57ySGYi3mLBeoBrNEjXUAkVtpxyT3pthCkkpjkZizHG4dB9aLtbvYXsla8jo9H1mK9BilcLNn5cnrirjOVm3MOD79KzdP0+3024csi7sfKfT3rUkXcisvIPPXkVLavdbHBUUVL3QuZA+2EDcz/AMqNqhxtGO3FUDIyXySqwKKu047VaknWLBY/LjoKLESi1oMvYsncjYY1Wv7loLYPn98oHTvVqCWK5AOchTgVT1ONR8zKxA5701vZlRtezMf7Te/88W/76P8AjRVv5f7sX5Citbvsa+72NlVyO1S7B19agU7mHUc/nVgNgHofauc5w28EjAIpVYdOTSBssuOmDx+VMKkndnvQCJAyK2e/b2pZJUwTUEzADk/jTdp29CO9BfKtxtxFJMdxHHYA01LTON/f07VYQEcDqf0pQ+1iOM+tFx8zSsiCSDKlVOBVD7OkLuycvnBrYfbnvjuc1WYK0nsOhqkyYtjLcEKAanKk4IpRkKoGafNLDAqieREZjgAnmi+pLT6DJnATnrVdc454qxMVz8wHFRPKrLhR+VCGhIWJJB6dqtQjaDnGaqox6Y5qeNyp5H4UmhsuKAQCTg9qRolzkt09qazAjg9PSgKzJnBAFSTqMZVkkAx8vrTVjlWUtG42+lDzLGCp7enc1JA42bjkr/OnYbuTCMD5sgnv9accFSGxg03l+AMClTGQBkjpxSsQMRPKTbkn+tMyGGDkYPpUssfIO8Y9KjLKVAOc5yDRa5SZDIY7WJ2ZimRjOcYqj9oiuZC1u+fXHrV8q3zRuqvGwIGRXHRaZrGn6qsUGPLkfJb+ECqSVt7M66FOM7tvU6FV+1HD9R2qeO2t7NCWRXbrvIqGS3kguC3mBmPUjpUM88pQu43KoxxUaPUqzeiehkX9t9o1FZiAyk8CtNStnKrqMJjAqraXBzgx9T1ParN2gZNwOV6gE1VlfU6JybtFmyLhTar5Q+XgVmS3MsV6gcHym4BHaq1rqBLpFHznituKIFF8wgt6H1p7dDjlFUnqVNRne3iWRSdpOCazbu0VbR7tv3pX5gB61tajAZLcIBkE8ikNsqxiLGBilcIVVFKxzSSzTKhaDG/timyobc+Xdyu8Tnof4a6WEDduMYO0YwKydS0ia6nim80JGW+bPYVUd9dDZV03qVY9OaeNo7YYUjAyataToxtImSRioPOQe9aUMS2xKQ5KkdTUp3NH8+ARwMc0Jt6X0Mp4iT0Ql40UVjiR9zjgE96rw3Z+zOjrjHCkdSKknmiWApJHv6AfWpoIxuLvHzjjjoKXSxkmkrsx9Og8mWRp2IR+SpNXgXks3aKPIyQCfSpxCJF3FQ3OOagivhDI0bptReAKbbkVKXNqkPsxvt8hMMOuOM1Hc3axWpEh2ueACM/nVpJoyMISu48CsnUrlJd1tcwlHU5VsY5prVkRi5S1JNsn9xaKz/Nl/wCe/wCtFVdGvJI3V3Adeacr7uM9KSNSoA7dASc9qc6ge3pWZz9RNx42n65pY/li5PyjnAHpUEhYY9vQVIpOB3JFDGkPY4HbJppc7gGIx7U7blfrSLHlgMmkVclEqJ14qG4YZ4IHsOtJIATgDnPX0qN4mDKx6j3pjSS1JFZSuGyfapGAKZxj2qCPORx9KtYBixQTLRjIGCnLZ9K5v+xJXv3uby6aQA5UA+9bxU54J4qM5IJbIHari3FOz3LhJxd0KZfMAXHWpo4dvbA9KiSNgN2OKuRKzDtjpU7IiT7FVCokYAEH3FXY0XbkkU1IVVySQW7DNNETMeTjjmkG5YULketTSEFVUdzzUMMK7wDn0q1sUj5D0qSGrMoBC2VdAOe4qUWpAJz8vbirO0NgsAPpUjZYDaCQeophzNFaOJ1TBZc4qdAEUKfxx3qUqMHtUDt8wC/eHP6Ubk3uNbrtI4x0qCYNj5R09qspuxh9oPtQRxkAE+9BSdihvlBBRcgdRUkgMwxIwXj16VK0bLnaMk0x42jySFJPqaTLTMaaG48mRRIAvY5qFlcWawjjPLMeprUkjZ3zIRwc4FUNRl/fxrHjGOgp6nXTnfQoMmz5VJPp7VPHCzIQ75bFQSO7t8wAX1qTzvJiZjkgiizN5Nsl020VLiOZgNyE4UVfE7m4JRenpWPaXZWQSyLkjgLirum3DSTyDHI9qu1tTlqxbbbNkSbzyaeXUuFPOKqJncuOAMg1YQDcCuOOvFTY5GhXjClinGeDk81AHUsYsHB7mrO0MCWY59KCQBgAZ9cZxQLmK/lgMWGTx0NRGdwvyIeParIz3x1Ofp/j0pHHcY5pjUu5mwTzSIwaA5zwTxUpu7xWYPDuQjoBmrYJLbQCx9alVZFGT970zSfoac66oyftN0EZ0jIVTyMVBeFBJGbkgTOQ6AVuMN4Kt3H0rL1GATzQqi75YjkHFNblwqJvYrTXiiTIGyReSDUFverqE4kl5KnODTNfkVZoztAcDDkVmsxO37PlWc4yOwoS0R1xpRcbnT/2mvoKKwP7Kl/56n8qKjlpdzP2UTpQaHJOexHrTRnggfSpFyx5AxVs40MVcIC3NPGDjnqe1SiPzOc8UipslHQgHrSBME6YA6VX3kgjGKW5vbSG8jtXuYRdSDKxFvmP4VGJQyh8EKwBGRg807FLUmQYUE5zTty9zyTUauHTuB0FC+/IpBYmRQTgDr61KE456A1EjIPT8KeH3EADvQQ7kbR4brn2ojg3Oc5wKlUbnxj8aswptBGcfSi427IgKApg/hTYSA+0Z571YKjfz0qKYBXBGOPSgUNdB6EM7KM+nNTGIovGWOOnHNVi0nmReXt27vnJ649un9a0YMFgBkn3qGymrEGzaQTnHtUgwFO1Tn6damRXKnzVw2eOOoxTkj+XjipuF7lcM3UpxTnc8cAZ609k5AX6e1PihIY5xx3oTE0is7EkAA/40BRkkmr0sKBVxg8flULxHb8qg4qydOhCqpGuFUDkngdSeTUclwqjAGWqWRAi5YjNUDKhmIfr7UxxjckdmnXC8EelQyngDJyOM1btiAx+UY+lR6iE8hicK2OKE9R3s7IyriSYZjjA575qlcKY5Buk3t79qsvOohO5gD6msZFkuJixbEdaJGsZOOo4Sq0hLOMA8j0qUMHXAUmo5beIxbY0/eZzk1rWyiG2iD4GF5AHtUyVjZVla5Qgt1fLsdu0/d6mti1gjhj3R8luuRViyWLkpCADwe9WQiEEFSDmpuY1qzloVyFEbMi5cjtTrMyeWBIACTU+1AuF6HvSgKOgxTuczelhpwMkDj86b8pU8YNPYZ46VH0IHagkbtG8nFBA3DAP6cUMCVIX7w6U2MMuA2c0xjvunPAHc1IJFaMEHj1qBsyNsPAI4NJaqoQx4+6aRVtBL67t7K0luZm/dxDJA7+1croniiPVLu5Z0W3T+AE9q1vFdoZdBu+cHAAHrXBs0GnWieXGPNKYcnuapNOLVtXoepgcJGrG50l3qFvIphdQfmyXz1rSjitVs1lRCCB1NeYy6sTy6nHYAVqaF4kmEn2a5DGJumRzVyoy5b2Omph46RhI6v7WfU/nRUP2u09G/Oisvax7Gf1KodC7/uyUwW7DHv7U6FyQpI+bHI96qq+BgkcDn0qeOQr3z+NNnlRWhei4GPeobmQZ/DtUJuiQVQkY9qaoJbLc0kNR6syo9EsW119VdZHumbdhm+UN647mtbGEORmnoCpwBSu+DjPPpTcm9yrJbES5CkcinITtBxmkABB5p8Y+XAxSBjl7j09afvOOMfypoAyQc+tIoIb5ehoJLMByWx6cUWsbxM7yOHJ6CiAAx49akA2AkHJ7mhEN9BXBI54P1pmMvuPCjnJplxPgfKOap3kNxe28YQjCtkY6g4xkfgSPxot3LpxNFGVjlSMZ4xVpS4wEP0rOtoDawhXOSOvtUkbuXOztyOMVmauK6GzGCCquwLnnFKkm9pFA27TjPr1qraSlpQJDyeMVciDSH5hgA5HvUMxtZ6ksSjHzcDvSSjBOwjb6+tOkYCPb1PtUeQcLgY9SSKSBkZBwe1M80quCfl7mpHACnnjvWeXZ7jyih2YzuANaIErjblXlIKglM1GbMFtzdewBq7IWEYHp6VApJXABJ9TVpi5n0GIPL/i+bGBz/Sql1au48ydz7Crqja+5gCetRTgyyKD0Bpp22HF6nOajayPGxRCWPSo9PtJre0K3Gc9a6gx/MdoGMVUltpHY9DnoapS6Mp1OZWMqOP5lAH456VpxxZj2qc+9MjtTFM3mAEHpirsEQRvmHy9qG7sluyJo32LtC9sdKRJN5PpTj1AH6U0fKPlXHtULQzeokkuCAvPbNG/K56VDPG5GY2we4pYg7R7ZBhh1NMdla5KXx3zmgkHGeMU0qMbck4phGV55X60E2HswAwOntTQ2Tgjg0YJ78LQOozTAQRsZdxPAHFSoCM47nNc54r1e502S0SzC75GG5WPOM10hyY42I/eMoLAdM4oadlLv+hcoOMU31M/Uz5hjgf7rkV5L4vZU8T3EcMoMSOcY6V67qIHlK5HzLyM1494ispbLXJZp4yYZnLq3XPNXh7e017HqYF/u7LujGeSTJZRknuaW3aU3cbOxwOTUl45MhMSnYTxSWtvPNOgVcEHkDrXfdct2dDjL2vKm3Z/I2Ptjf5FFO/sy5/55NRXHen3PX52eiQZZMsAD7HtU2wmPOcfjRtxjH8qkRXBJOSpxxjp9P/r1lI+PiLZKNo6tkcVLICDwM+lKyKygMisB6gGkIZ+uRUlgpIzimEY5PccVPCnJOAB/hTbkAZOM4oJctSIck47U5Dgc+tVonbDY/KnbiFBOaZTRa3FicYNSxKN3zdKghAPXJq5GAR9KTIbsDtjGzvTWzsxkA/WmSNt+7yfrUX2gt1XAHrTJUWSKwc4IGBUqkDaFyPeq6spbPIFPgQrcM5Y4I6dh0pMuxbZs8Y4PeplQK1RRjL55wKnA2jcx47DvUMh6B5edyq7I5HDLjK9s1chfoBxxUKgNhiOemTTwD16VIrkk08cRBJIJ4pHk3AEDFVZzuwCehzg9qSSbCgcZoURj55jkgVAknPQVCz4PXmnBxk+gq7FLQsJcZHynJpFyFJbjPvSRdCxA56U513HBLUzNkUx3YCnHrSQ4UnJ6nFShBu4zj1NMMZJ4HOaCk1YkYkKPenAjp1A7UcqpzUCMqqSSeKRNrjmRfNzxgc4xSFcsSMVR1jVotLtluJEZwxwAO1O0y/g1G2Fxat8nQr6Gqs7c1tCnCVuYuNld2DgmmW5fBEnX2zikYszkL6UCXJIwQaCLD2w3zdVPtTchACWJyfTpTs/IB1NQyLuYZ7UAvMkJGTyeKY+DHwBn1pgk5woIGOo7UxDkYHY0xpD23KOOST60qE4HQUilck5yMUuFLZJwOvFK9lqFtbFC+0qz1C8hmuYmeSLlSDitBnI44wOBz2rltH1ia71i/wDtbiHTkBUEnHPat5IwqJsfch5B45qpJxaizapCSspDpWUnaehz3zWTqWnWt1YNa3illZsqw6qfatRkJwWbn0pZF4+UAg+oqWrlU6jpO8TzK/8AC17aNixxcQk/KcjP41Y0TQ7yzn826iHm5yFBBrt5o4Ft2Kuwkzzg1Fbt5xCrwW4LGqc5uLTdz0Y412ulsZu26/55j8xRWl/Yy/8AP4f++hRXPaHb8GT9b/vFpNvBwenfrU/RSAAKjYDaOBkDIApw4AyPvVs2eakIzEYDEDPHXBNRsHGMY9qexwoPOaieQkkelBSLPmYQZPaonlDJnPXsOahLZTYWwPrTreEFwc+4FNCaS1HrHsQ8ZJ9qildQM8EdyCDWjJGFT3NZ7RKgIA/XNAQfMJHJ029KsRyt0z14pqoNvfNOCnHfilcbSGlySR3ppySeO2alVAQM8HNPZArDHpzTuF7ESnJB4q3AueD0HrUaADnHWrDbiqtCCR2x60tyZSLUSYG0YAx2p7qSVHRarm4MFvJKyF2RSwQdzWHoGoavqWqSXN1D5VjyAPf0Ao5W05dhRpuSb7HVM3IxSPIwBqMnPQ1C0hDbRn1yalIysOlyoG4nNVixbOOgqww3AE5JqNlGcDrTRa0IZFBTOMmmRncDnn+tLJncMUpVtvbnrVDLiufLBAGAKPMDDOeKijYLHk8+op0Z8xMMRnvjikRYep3D5SC2cHH9RQ7FTgnn0qONYoZXZQd5Pr+NNlZXwM856Ck0NK7J264NR71T0x1x3oIGAuST9aTYDnK9OlAFSWIXb7J4wYfQjrUlvaW1nEIrOPy4+uMdTVkAEdP0pmR1JwetMbm2uXoKW25zjJph5HbPrQWBVsMKYxIkyw+QDIouSlqP34PFQyEgDGMUO4kwsYyfeo50IkGTn2oHawCV0LF1GO1RmUKzYOcnjPrS7T5uCM+2aawG/JGQDVFKxNG2UGXy3fAxTgWCswG5scAmoYwN+Bu3HqKckbKTkkkUgaMLxDpt1qE9paw2ipbyHdIy/Kc561vxQJbRrFGSVRQoyc9KaskU935Qm+dBkqPrj+dSXEYA2rzzRfRR6I0nUckosNyLlpG5HpVJ5jcOVQFUU9ameMPjK9O+aWSQZCBQKEQtDPvXWO3Jhjyx4HvTYrczwrwAOp3LjGDzwR9atRKPtZmkA2gbVHbNMkllimBAyR/DTLctLIPsTf3l/If4UVQ+1Xn/ADz/AEop8kvInll3NpFB4NOYK3AB4qFWBOcA09DgnPeoaJQxlweCcnv6UqxhuScAU6QjJA61GeuD3oZSu0V5sedgLgetSRt5UgYfeA4FNVGMpyRg0pwsnqRTLt0Mi7n1D7WDI21CflUd61omYqit97AzT2dLpQWQhxwGNIEMcYy5J9TRLU0500lYt28JbkE49alljxg1nT6pHptk8soJPZcd6j0jWV1OGRhGVKng+tLlduboZOnN+90NARjO7OKXYDyScmoXlyQKmQhSOABnPHagl3RZgi2phgKZNN5ThYlyR0qK5ukTjNU/OLtvHAp20JhBy1ZprMD8xJz6VPIVaH5QAOuBWUrENuIBJq7BNu2pjipt1HKNthkc7htrZ61JLvXbnPP60t2DuUqvTqcUSEFgSenGKfUV76oljO0kHketNc7m9ulIfu5A49c0xMt9evFAl3Hso456+lMkUhAByTT2Ug8YBx1pjo2AR196ARDIG2rSLNhlRAQepNSbehJH0pI1yrE49sUF9CwgQLnG4n1NJlHmKqDke3Sq7yAxjY2MHpVmAgqGHX6UNEPTUVkO4kgjtSpkCmzs4O5enUg0kUnmqcLhe5pC6D2PbOc01lBAI6D0pc87QOntSYIGB+eKEJlUnCM7EgKelIs8ZXduAGOhp1wskn7tWxnqTUC2aLIFY5NUWrW1JJJGTDKuFPoKUN8wJI56Zpz4AAY8AcVDd31jZtBHeSBZJT8ijrQk3ogWuyJ229SfvHrTQCM7V/Opp/LiZFRXO8EhguQMY6nt14qNySM5xt5pJ6Eke5TKV6MB0FSRllBLZ+lOWNWJkB+bGKjLDcMtn1pjuU4bIDxDNew7QrpyPTOD/MVeeWGJW82QA5xVXEkE5MYxEwySazNTng/tS0gAZnmORnoKpLmaRoocxsXcxjQbckEdBVeeTy1jRQN8v6VakKRMkRAJPyj34zUflBrlXkGAB8tJNGd0hltAYzkksoHGaguJDHG0r5Lk4VR9auSSYXgCoXRHjMkmflBxgc/hTT1uyb9WV8S/88z+tFLh/wC+35j/AAop3fYdyRCQRx09O1SLlV557/So4jxyOalVvwqCrCYwcGhlOOO1PxnvTlIVcUh3K7hiOOvbNQoh/iJLetWvLySW4zSBACc9KZfNZDIyo6jn1pJQzjAFBI3r9fTPapG6cEUC5rO5C9tFPHsuIwwp8cEUMW2NAq+gFWIArcZ59KfNGFWpD2j+Eo4JYBQcmpbiQQoN3PerFqilQwxn3GKh1BlV9pwapCvzSsZ7zbuQAc06EsxyenvSFgvuTwCO1WbWE4Usc5oZtKSihVGTnPFWYynAcKy+hGfpSSRZ+5T1jyoBPP8A+qkZOSaLe8uw9Mdqj8+Fi2zG4HGPWo4yF6k4/SpAI24UAeuKDOyQvm5XBAHpTLf5STSvGeBnNR78EBe36UDWxeGAOev1qKXL/cGKaCSOaXzCnIyRQQtCMKQW3daSPoNhyTSyHcGAB3CpbdVEI5HPOaC+bQpukn2g/L8vWr8Q+UcYGKb/AAsEb5jSx7goDNlqGTKVxtwGKuqHDNSxo0dvtY5PXNO3qW7flSNJwRQTfSw2LkHJ56CnMGx8g/M01VXGUGKkRu3FAMilRjyBimbQJF6Z6+tWSQRywNRysh4B+b60CV2ULyPajNuOR1+lYnifTZ71rKaxt1kljbhm7CugaWFX8ubcWY4HoPc1PHtiUFyFPQZ5qlJxaaN4VHT1GQRTRwxiYhpSBu9M1EZA0zIw4HBpTeIJiCdxJ4C0yEGWVmI2jPTPWlsTrduRKFK9sIfeiGBGcsDuPYUkTSSTTAgKqcDJ61CyywQM65DY4+tDdgSvoW71PNgMLD73p2qJIIAVbajSRDCnHIrnvDyaxb6lI+rTmSBwSApzjNbzyJCwjTLs7ZJxTcbPlTv6DlFw91MtR8ptzyeTWfO8ksrIBtReh7mrcu/AZOPaq6K63DHgR9WHv60l3M0ragjwxskUki+cRnbntSSACRtw4Tr2xWVdaOZNaj1BJ2+XGVB4NatwztuC4BJzg9qrTSzHOKWzJcf7I/M0VT/df9Mfz/8ArUVPKZChgVByc0qZO7tUY6+9SoTzjt0xTZ0Dskfe+lPXB69KrOx3cipoju9aQNDPPjkupII3zJHy3BA4xkZ74zTJVYj5W571MIUWRmWNA7Y3MFGW+ppWiOPpQxp2IYxgYPJpSQOvemk846H0pwBY8cmgCaIZ5U85qZ8GIBjub2qCI7DtbimXEoVsL0zSsS9WOaUo21BiopU8xSzH58YBxkA+uKrXMpDc85OKjkkZuN2AavlNIrqXrKJtmJmDsCcH/wCvjmrqKMABcYqppsgCBTzV3ljw2BUmc3rYkiX5TnoP1qF3UPxwT1PfH+c02aUwjCtuz6U2KVXALgZzzSDl6ilycBRg9waeCU5pvy5JphJLADkZ6U7ATBw2OTmiOPIZuOfWo1IBxiiZyIztJJHvQHoTSMFRVHU1OkSiMb+v1qjBD5rKWJHerpaNFwOVFBMtNESBAUwuce9V3faNrHA61n+IIb+8ghl0yTYIssyA43VHpV7e3UDm/tzE+cAEYotpe5cad48xoQtkk8+1Tqcn2z6VUBZFwRj3FKZy7BEPPrSIcbsWYOJSFJx9Kk8skYIBx170m7H8QOT25otppRCoaMfe6bskZPHbtmgGyaPpt+6Kau1XIJJc9akjLsuT/wDqqC6VgxK/LkYNBK1dh4aIxkEYA700RqXypB3DcDntUVgiGKU5ImJxlv5UxLaa38y4uplLyfKqJ2FDLtZ2GyqskyJjkHIbHT6Ul3DGHQtISo7Yq/Gu1FwuTjriqkp3TrwCQafoOM7kVjbMlw0oOB2yOasxIEBdn+cnNPHLZ/rUMduFJaVt2O1G4nLm3M3zrj7dIj5CluG9apQ2utLr/m3Fwp089RXSuA+GYDp8uO1NGxE2E8dcE1SlbZeRarabDFtgP9YuSOhz2pHC/alUKNwyWIp8kwUYB5xximWx2SsW6sKlbGV3uxbmKaU5Rtqd+KgjMjyYjYAg8mrLlUVizdaSFAIT2zzj1poL6FWMiGcp8oj9egB9PoajnlIZjjOTgAVaxsdsJnd2HeoJlKRhYlOAfvHjHOfy5/SmhaFTzp/70f8A38/+tRU3m23/AD7wf+Pf40U7oVwwMccU8Ajr396jCnP1PSlZskAkcGpNx+0HHripEyDn0pF2ZBB4ofIYAfdHWgRMj46fTpUkjDZ6/So0XIzyGNNkKk7PmJ6j0pENELpyW9aajFJMnpTwWwQQOPSmAcjJPNNlp9BZ5QGBBNULm5RYyzEL7k9fp61blCnjJOelZd9bQyNukBOO2eDTSKRXa5eRhzkfSpmlKgd/Wq4wT8gAA7AYFKjMZNtX0DW9jTtbgJgY6elaVsxdDzisq3RflJHNasAwvt1rNjkkTGAAjJBJ96HXuMZPpSKeevFNkkwQM5FBldsUghRg4PamoSHHFKH3Hp/SlAJPY0ANLfN6j2qeDG3Jx/SmKmG60/ywRkn5aQNjkyZCZDn8akZI1TGevekh2kbT1HanswVSQoY7TtXP3iBxQyG9RFO1R5RznvUMsfzglsmjT1ufsqvfFRKWOAOoHbPpnk49MVJhZG68DkmkxqVhlzlcADIp6pGEyQAcdRwae6qwAQjA9/zqKSLAA6jGaYr30HKiRsWU5pxwMMOe+Ki2fL87BQKfFtkHAOBxmiwMlkcJFkDtzWfPPmMgnpzzVuUnG0cDpzWVqEBMbBDwOtNIFYmt76DG0EA1MkbXEhaRsKBlfrXOxQlHjKqc5roLb5cDBH1qpRsNu2xYin2Dax9feokc7y6qffNKFV5N2ML3Pp+VSpneynG3FRYLpCRM7OcKAox+NLsL5L4Apdu18KSW9KY4YttZgO/0pkX7Di38IP5VEkR80l+acH2DCjJ9fWpM5I5Ge4zRsO9hHSNWJ2jp+VRWzCeaTaOF43difT+VL96UKTnaOc9/epVXaAQBtoAixvlYLzjvTnBULkYA6YFKZVjTPXmojIrnJHPTP9P8+tAChmb7vGOeaqXY8xdjqcZwQRnPPX6dKmaT52GMdqqyqp3KuGfsCcA/j+X0poLCeXB/z7x/5/4DRUW76fkf8KKd33JJpHwrMTsVcE89B1pruP8A9dShPlPmhT1J74FVwFAPIB6YzSN4u4quRkgmlM7BulRlcFN4HU4xk4/yKfEgYjccgDHzc0iy7BMCPmGDj+lNc7myBgVCyhXC5HNBzt3dCfl96CeVbk0RwM9e9LuBHI/+vTIcnknIHAzRImBwueRwOvWghkcqnPFUZUbnOD9a02XC5zx61BJE3GNuO4I60y4yMsR4HTH0FSQQ5PTn1q7DCrNzjn8KlijIY5xx6d6LlXsRRRbQCev0rQgQBO3PFV1XLYyPUAnnHTOPrQ8asysDiQKyBgcEA4z/ACH5UmJu6LYXA7U0xkkZAx37UwSHgDOB39qmM6h1Qq3IJzjjjHft1oMndAsW04BpURQx7f1oyNwY/SlhxubGRzg5U8nH+eaBNgc7unX9KPNZDhVJxzTmJPTOD156e9Rqx2kdBnGe3T+X1x/KgVyU7lGVXnr9KQg+WC4w3tzTkzuOQeMDOKiLlsblAbHI64oBbi72cN2GfxJx2qOHcAwKkH3pHu1iQ7VyeuQM5/GooZ3lUM4+UjOCODzRZlJF2OVs42n0p00yq6qRhiarRyMWCxqFXsKbPIVO4guf4SO1FhW11JY0ZZiWbI69aknuUQjoPWstbndKN7MgPOMfSrV9afao4tjgIBz60W7ltJNcwoumnmEMWcA8tV14lYYHIxzVK3Cq22FT5arkk96lin3EBd3ODhlIPPTryKGuxMrdBPsqLyFGewoRN5I7r1qaSVY1wzfMfeoUZlOcgZ696NSUG9UXHXvwaaZi8ZKjBH41HK6u2FAGO5qdY12DPzHGcE8fnTDRbixD5SwbJPrSMR1LZ5pHZVGDuHYLUICtP3wOh9aBXuOE5NwE2kU4yfOBg7vT3piylXO9cnJwQMYFKzqJWbBwBxgEn9KYyZYyrkn60rScZ6gcVEfMwAG5PPrxnmjcoQ5yFXljjNT6jCdSWJViSc8Y6VWdZCUVAfl5JH+frU4cMFZTt3AY3ccHnketBKRW77GyvViSPSmmF7EU7iNS8rfKO4qu3kAMyvh+vJ/PipZXH2ViQO+Bkf8A1uv+c1yWteIIbTSZnj1JDdY2iMoAQxPQoeQQBj9fY1GLlohXSNv7dH/eP5JRXkf/AAlOrf8APwP++RRXZ9UkTzw8z//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells and Gram negative diplococci. Moraxella (formerly Branhamella) catarrhalis grew from this patient's sputum. Although encountered less frequently, either Neisseria or Acinetobacter could have this appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_51_16191=[""].join("\n");
var outline_f15_51_16191=null;
